1
|
Han J, Tan X, Wei Y, Hu Z, Yang Q, Zhu Y, Chen Z, Zhang Y, Yu H, Cai X, Cui S. Gestational Diabetes Mellitus Rats Induce Anxiety-Depression-Like Behavior in Offspring: Association with Neuroinflammation and NF-κB Pathway. Mol Neurobiol 2025:10.1007/s12035-025-05033-x. [PMID: 40360956 DOI: 10.1007/s12035-025-05033-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Accepted: 05/02/2025] [Indexed: 05/15/2025]
Abstract
The gestational diabetes mellitus (GDM) rat model was established through a combination of high-fat diet and streptozotocin. GDM is a common disease during pregnancy with high morbidity, which is associated with a high risk of neurological changes in the offspring. Neuroinflammation plays an important role in the development of anxiety-depression-like behavior. However, the mechanisms involved are unknown. This study aimed to investigate whether GDM induces chronic neuroinflammation in the offspring, resulting in anxiety-depression-like behavior. Our study used high-fat diets and streptozotocin to establish a gestational diabetes rat model. Eight-week-old offspring were assessed for anxiety-depression-like behavior using the open field test and the modified forced swimming test. Prefrontal cortex (PFC) tissue was observed by H&E staining. The expression level of peripheral and central inflammation was monitored by ELISA. Differentially expressed genes in the PFC were detected by RNA-sequencing. The results of RNA-sequencing were verified by RT-qPCR, Western blot, and Wes™ Automatic Western Blot Quantitative Analysis. Anxiety-depression-like behavior was observed in the offspring of GDM. It indicated that PFC neurons were impaired and neuroinflammation was more serious in the GDM offspring, in which the increased concentration of CXCL10 was observed. Moreover, it revealed that the PI3K/AKT pathway was enriched by KEGG analysis. Mechanistically, GDM increased astrocyte activation and facilitated the nuclear translocation of phosphorylated-nuclear factor-κ B (p-NF-κB) in the offspring. The development of anxiety-depression-like behavior in the offspring of GDM rats was influenced by neuroinflammation in the PFC. These effects may be associated with astrocyte activation and activation of the NF-κB pathway.
Collapse
Affiliation(s)
- Jing Han
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
| | - Xiaomu Tan
- Department of Neurology, Beijing Xiaotangshan Hospital, Beijing, 102211, People's Republic of China
- Department of Neurology, Luhe Hospital of Capital Medical University, Beijing, 101149, People's Republic of China
| | - Yuchen Wei
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
| | - Zhuo Hu
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
- Department of Clinical Nutrition, Xi' an Daxing Hospital, Xi'an, 710016, People's Republic of China
| | - Qian Yang
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
- Department of Clinical Nutrition, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, People's Republic of China
| | - Yandi Zhu
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
| | - Zhaoyang Chen
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
| | - Yadi Zhang
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
| | - Huanling Yu
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China
| | - Xiaxia Cai
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China.
| | - Shanshan Cui
- Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing, 100069, People's Republic of China.
| |
Collapse
|
2
|
Cheng W, Yu C, Liu X. Construction of a prediction and visualization system for cognitive impairment in elderly COPD patients based on self-assigning feature weights and residual evolution model. Front Artif Intell 2025; 8:1473223. [PMID: 39991464 PMCID: PMC11842389 DOI: 10.3389/frai.2025.1473223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2024] [Accepted: 01/13/2025] [Indexed: 02/25/2025] Open
Abstract
Background Assessing cognitive function in patients with chronic obstructive pulmonary disease (COPD) is crucial for ensuring treatment efficacy and avoiding moderate cognitive impairment (MCI) or dementia. We aimed to build better machine learning models and provide useful tools to provide better guidance and assistance for COPD patients' treatment and care. Methods A total of 863 COPD patients from a local general hospital were collected and screened, and they were separated into two groups: cognitive impairment (356 patients) and cognitively normal (507 patients). The Montreal Cognitive Assessment (MoCA) was used to test cognitive function. The swarm intelligence optimization algorithm (SIOA) was used to direct feature weighting and hyperparameter optimization, which were considered simultaneous activities. A self-assigning feature weights and residual evolution (SAFWRE) algorithm was built on the concept of linear and nonlinear information fusion. Results The best method in SIOA was the circle search algorithm. On the training set, SAFWRE's ROC-AUC was 0.9727, and its PR-AUC was 0.9663; on the test set, SAFWRE's receiver operating characteristic-area under curve (ROC-AUC) was 0.9243, and its precision recall-area under curve (PR-AUC) was 0.9059, and its performance was much superior than that of the control technique. In terms of external data, the classification and prediction performance of various models are comprehensively evaluated. SAFWRE has the most excellent classification performance, with ROC-AUC of 0.8865 and pr-auc of 0.8299. Conclusion This work develops a practical visualization system based on these weight attributes which has strong application importance and promotion value.
Collapse
Affiliation(s)
- Wenwen Cheng
- Military Preventive Medicine School, Air Force Medical University, Xi'an, China
| | - Chen Yu
- Military Preventive Medicine School, Air Force Medical University, Xi'an, China
| | - Xiaohui Liu
- The 986th Hospital of PLAAF, Air Force Medical University, Xi'an, China
| |
Collapse
|
3
|
Sola T, Sola FM, Jehkonen M. The Effects of Type 2 Diabetes on Cognitive Performance: A Review of Reviews. Int J Behav Med 2024; 31:944-958. [PMID: 38467963 PMCID: PMC11588889 DOI: 10.1007/s12529-024-10274-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/27/2024] [Indexed: 03/13/2024]
Abstract
BACKGROUND Multiple systematic reviews have found that type 2 diabetes is associated with cognitive decrements. However, these reviews are heterogeneous in terms of methodology, quality and results, making it difficult for researchers and clinicians to build an informed overall picture. We therefore conducted a review of systematic reviews on the association between type 2 diabetes and cognitive decrements in relation to healthy controls. METHODS Following a pre-registered research protocol, we searched four major databases. Nine systematic reviews met our inclusion criteria: seven were meta-analyses and two were narrative syntheses. We assessed the risk of bias in each review and reported all effect sizes and confidence intervals obtained. RESULTS Type 2 diabetes was associated with cognitive decrements in all reviews, with small or negligible effect sizes obtained in the largest meta-analyses. The most studied cognitive domains were attention, executive functions, memory, processing speed and working memory. All reviews had methodological issues and were rated as having a high or an unclear risk of bias. CONCLUSIONS Type 2 diabetes appears to be associated with lower cognitive performance in several cognitive domains and in different age groups. However, high-quality meta-analyses on the subject are still needed. Future reviews must follow the PRISMA guidelines and take into account the risk of bias of the original studies through sensitivity analyses and the heterogeneity of the studies by conducting subgroup analyses for example according to age group and disease duration. The meta-analyses that aim to study the entire type 2 diabetes population without excluding severe comorbidities, should assess concept formation and reasoning, construction and motor performance, perception, and verbal functions and language skills in addition to the cognitive domains that have been most frequently analysed in the reviews conducted so far.
Collapse
Affiliation(s)
- Teppo Sola
- Psychology, Tampere University, Tampere, Finland.
- Tampere University Hospital, Tampere, Finland.
| | | | - Mervi Jehkonen
- Psychology, Tampere University, Tampere, Finland
- Tampere University Hospital, Tampere, Finland
| |
Collapse
|
4
|
Hayes-Larson E, Zhou Y, Wu Y, Mobley TM, Gee GC, Brookmeyer R, Whitmer RA, Gilsanz P, Kanaya AM, Mayeda ER. Heterogeneity in the effect of type 2 diabetes on dementia incidence in a diverse cohort of Asian American and non-Latino White older adults. Am J Epidemiol 2024; 193:1261-1270. [PMID: 38949483 PMCID: PMC11369220 DOI: 10.1093/aje/kwae051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 01/25/2024] [Accepted: 04/16/2024] [Indexed: 07/02/2024] Open
Abstract
Dementia incidence is lower among Asian Americans than among Whites, despite higher prevalence of type 2 diabetes, a well-known dementia risk factor. Determinants of dementia, including type 2 diabetes, have rarely been studied in Asian Americans. We followed 4846 Chinese, 4129 Filipino, 2784 Japanese, 820 South Asian, and 123 360 non-Latino White members of a California-based integrated health-care delivery system from 2002 to 2020. We estimated dementia incidence rates by race/ethnicity and type 2 diabetes status, and we fitted Cox proportional hazards and Aalen additive hazards models for the effect of type 2 diabetes (assessed 5 years before baseline) on age of dementia diagnosis, controlling for sex/gender, educational attainment, nativity, height, race/ethnicity, and a race/ethnicity × diabetes interaction. Type 2 diabetes was associated with higher dementia incidence in Whites (hazard ratio [HR] = 1.46; 95% CI, 1.40-1.52). Compared with Whites, the estimated effect of diabetes was larger in South Asians (HR = 2.26; 95% CI, 1.48-3.44), slightly smaller in Chinese (HR = 1.32; 95% CI, 1.08-1.62) and Filipino (HR = 1.31; 95% CI, 1.08-1.60) individuals, and similar in Japanese individuals (HR = 1.44; 95% CI, 1.15-1.81). Heterogeneity in this association across Asian subgroups may be related to type 2 diabetes severity. Understanding this heterogeneity may inform prevention strategies to prevent dementia for all racial and ethnic groups.
Collapse
Affiliation(s)
- Eleanor Hayes-Larson
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| | - Yixuan Zhou
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
- Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| | - Yingyan Wu
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| | - Taylor M Mobley
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| | - Gilbert C Gee
- Department of Community Health Sciences, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| | - Ron Brookmeyer
- Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| | - Rachel A Whitmer
- Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, CA 95616, United States
- UC Davis Health Alzheimer’s Disease Research Center, University of California, Davis, Sacramento, CA 95816, United States
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588, United States
| | - Paola Gilsanz
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588, United States
| | - Alka M Kanaya
- Department of Medicine, School of Medicine, University of California, San Francisco, San Francisco, CA 94143, United States
| | - Elizabeth Rose Mayeda
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, United States
| |
Collapse
|
5
|
Jain A, Sunder S, Jain N, Yadav N, Saini A, Yadav KS. Study of cognitive functions and their association with depression in type II diabetes mellitus. J Family Med Prim Care 2024; 13:2323-2328. [PMID: 39027822 PMCID: PMC11254044 DOI: 10.4103/jfmpc.jfmpc_1150_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 12/06/2023] [Accepted: 12/10/2023] [Indexed: 07/20/2024] Open
Abstract
Introduction Individuals with diabetes have higher risk of developing depression, cognitive impairment, and dementia compared to those who do not have diabetes. The present study aims to assess the level of cognitive functions and the presence of depression in diabetes patients and healthy controls. The study also explores the level of cognition among the normal control, diabetes without depression, and diabetes with depression. Methods In the present study, the presence of depression and the level of cognitive functions of 59 cases of diabetes mellitus type-2 were compared with an age- and gender-matched control group of 40 individuals. Clinical and demographic details were recorded on a semi-structured performa. Montreal Cognitive Assessment (MoCA) and Patient Health Questionnaire-9 (PHQ-9) were applied to both diabetes patients and healthy controls to assess the level of cognitive functions and the presence of depression, respectively. Results On applying odds ratio (OR), it was observed in the present study that there were 93.50% more chances [OR 1.935 with 95% confidence interval (CI) being 0.481-7.789] of depression among diabetic cases as compared to the control group. Similarly, the chance of MoCA score being less than 26 was twice among the diabetic group as compared to the control group (OR 2.208 with 95% CI being 0.702-6.946). On application of the Chi-square test, the association of depression was significant with HBA1C level, level of education, and presence of complications. Conclusions Patients with diabetes had almost double the risk of developing depression and poor cognitive functions as compared to the healthy control. High HbA1C level, level of education, and presence of complication in diabetes had a positive statistical association with depression. Thus, it is advisable to investigate patients with diabetes for the presence of depression and cognitive dysfunction by applying simple tools.
Collapse
Affiliation(s)
- Akhilesh Jain
- Department of Psychiatry, ESIC Model Hospital, Jaipur, Rajasthan, India
| | - Shyam Sunder
- Department of Medicine, ESIC Model Hospital, Jaipur, Rajasthan, India
| | - Nitesh Jain
- Department of Medicine, ESIC Model Hospital, Jaipur, Rajasthan, India
| | | | - Ashok Saini
- Department of Psychiatry, ESIC Model Hospital, Jaipur, Rajasthan, India
| | - Kuldeep S. Yadav
- Speciality Doctor, Adult CMHT, Somerest NHS Foundation Trust, United Kingdom
| |
Collapse
|
6
|
Cao F, Yang F, Li J, Guo W, Zhang C, Gao F, Sun X, Zhou Y, Zhang W. The relationship between diabetes and the dementia risk: a meta-analysis. Diabetol Metab Syndr 2024; 16:101. [PMID: 38745237 PMCID: PMC11092065 DOI: 10.1186/s13098-024-01346-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 05/04/2024] [Indexed: 05/16/2024] Open
Abstract
BACKGROUND The link between diabetes and dementia risk is not well understood. This study evaluates the factors linking diabetes to dementia onset, providing guidance for preventing dementia in diabetic patients. METHODS This analysis utilized databases such as PubMed, Embase, Web of Science, and the Cochrane Library to review literature from January 31, 2012, to March 5, 2023. Articles were rigorously assessed using specific inclusion and exclusion criteria. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the studies. Data analysis was performed with STATA 15.0. RESULTS The study analyzed 15 articles, covering 10,103,868 patients, with 8,821,516 diagnosed with diabetes. The meta-analysis reveals a substantial association between diabetes and an increased risk of dementia [RR: 1.59, 95%CI (1.40-1.80), P < 0.01, I²=96.4%]. A diabetes duration of less than five years is linked to a higher dementia risk [RR: 1.29, 95%CI (1.20-1.39), P < 0.01, I²=92.6%]. Additionally, hypoglycemia significantly raises dementia risk [RR: 1.56, 95%CI (1.13-2.16), P < 0.01, I²=51.5%]. Analyses of blood sugar control, glycated hemoglobin, and fasting blood sugar indicated no significant effects on the onset of dementia. CONCLUSION Diabetes notably increases dementia risk, particularly where diabetes duration is under five years or hypoglycemia is present. REGISTRATION The research protocol was registered with PROSPERO and assigned the registration number CRD42023394942.
Collapse
Affiliation(s)
- Fang Cao
- School of Basic Medical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Fushuang Yang
- College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Jian Li
- College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Wei Guo
- College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Chongheng Zhang
- College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Fa Gao
- College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Xinxin Sun
- Department of Nutrition, Chinese People's Armed Police Force Medical Characteristic Center, Tianjin, 300162, China
| | - Yi Zhou
- Department of Geriatrics, Baotou Mengshi Hospital of Traditional Chinese Medicine, Baotou, 014000, China
| | - Wenfeng Zhang
- School of Basic Medical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, China.
| |
Collapse
|
7
|
He WL, Chang FX, Wang T, Sun BX, Chen RR, Zhao LP. Serum brain-derived neurotrophic factor levels in type 2 diabetes mellitus patients and its association with cognitive impairment: A meta-analysis. PLoS One 2024; 19:e0297785. [PMID: 38648255 PMCID: PMC11034647 DOI: 10.1371/journal.pone.0297785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 01/12/2024] [Indexed: 04/25/2024] Open
Abstract
OBJECTIVE To compare the serum levels of brain-derived neurotrophic factor (BDNF) in type 2 diabetes mellitus (T2DM) patients with healthy controls (HC) and evaluate the BDNF levels in T2DM patients with/without cognitive impairment. METHODS PubMed, EMBASE, and the Cochrane Library databases were searched for the published English literature on BDNF in T2DM patients from inception to December 2022. The BDNF data in the T2DM and HC groups were extracted, and the study quality was evaluated using the Agency for Healthcare Research and Quality. A meta-analysis of the pooled data was conducted using Review Manager 5.3 and Stata 12.0 software. RESULTS A total of 18 English articles fulfilled with inclusion criteria. The standard mean difference of the serum BDNF level was significantly lower in T2DM than that in the HC group (SMD: -2.04, z = 11.19, P <0.001). Besides, T2DM cognitive impairment group had a slightly lower serum BDNF level compared to the non-cognitive impairment group (SMD: -2.59, z = 1.87, P = 0.06). CONCLUSION BDNF might be involved in the neuropathophysiology of cerebral damage in T2DM, especially cognitive impairment in T2DM.
Collapse
Affiliation(s)
- Wan-li He
- Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China
| | - Fei-xia Chang
- Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China
| | - Tao Wang
- Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China
| | - Bi-xia Sun
- Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China
| | - Rui-rong Chen
- Department of Medical Imaging Center, Gansu Provincial Maternal and Child Care Hospital, Lanzhou, Gansu, China
| | - Lian-ping Zhao
- Department of Radiology, Gansu Provincial Hospital, Lanzhou, Gansu, China
| |
Collapse
|
8
|
Grasset L, Frison E, Helmer C, Catheline G, Chêne G, Dufouil C. Understanding the relationship between type-2 diabetes, MRI markers of neurodegeneration and small vessel disease, and dementia risk: a mediation analysis. Eur J Epidemiol 2024; 39:409-417. [PMID: 38190014 PMCID: PMC11101545 DOI: 10.1007/s10654-023-01080-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 11/03/2023] [Indexed: 01/09/2024]
Abstract
To explore to which extent neurodegeneration and cerebral small vessel disease (SVD) could mediate the association between type-2 diabetes and higher dementia risk. The analytical sample consisted in 2228 participants, out of the Three-City study, aged 65 and older, free of dementia at baseline who underwent brain MRI. Diabetes was defined by medication intake or fasting or non-fasting elevated glucose levels. Dementia status was assessed every 2 to 3 years, during up to 12 years of follow-up. Brain parenchymal fraction (BPF) and white matter hyperintensities volume (WMHV) were selected as markers of neurodegeneration and cerebral SVD respectively. We performed a mediation analysis of the effect of baseline BPF and WMHV (mediators) on the association between diabetes and dementia risk using linear and Cox models adjusted for age, sex, education level, hypertension, hypercholesterolemia, BMI, smoking and alcohol drinking status, APOE-ε4 status, and study site. At baseline, 8.8% of the participants had diabetes. Diabetes (yes vs. no) was associated with higher WMHV (βdiab = 0.193, 95% CI 0.040; 0.346) and lower BPF (βdiab = -0.342, 95% CI -0.474; -0.210), as well as with an increased risk of dementia over 12 years of follow-up (HRdiab = 1.65, 95% CI 1.04; 2.60). The association between diabetes status and dementia risk was statistically mediated by higher WMHV (HRdiab=1.05, 95% CI 1.01; 1.11, mediated part = 10.8%) and lower BPF (HRdiab = 1.12, 95% CI 1.05; 1.20, mediated part = 22.9%). This study showed that both neurodegeneration and cerebral SVD statistically explained almost 30% of the association between diabetes and dementia.
Collapse
Affiliation(s)
- Leslie Grasset
- University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, F-33000, Bordeaux, France.
- INSERM U1219, University of Bordeaux, 146 rue Léo Saignat, 33077, Bordeaux cedex, France.
| | - Eric Frison
- University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, F-33000, Bordeaux, France
- Service d'Information Médicale, CHU Bordeaux, Bordeaux, France
| | - Catherine Helmer
- University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, F-33000, Bordeaux, France
| | - Gwénaëlle Catheline
- INCIA, EPHE, CNRS, Université PSL, University of Bordeaux, 33076, Bordeaux, France
| | - Geneviève Chêne
- University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, F-33000, Bordeaux, France
- Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000, Bordeaux, France
| | - Carole Dufouil
- University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, F-33000, Bordeaux, France
- Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000, Bordeaux, France
| |
Collapse
|
9
|
Sempere-Bigorra M, Julián-Rochina I, Pérez-Ros P, Navarro-Flores E, Martínez-Arnau FM, Cauli O. Relationship between Cognitive Impairment and Depressive Symptoms with Somatosensory Functions in Diabetic and Non-Diabetic Older Adults and Its Impact on Quality of Life. Life (Basel) 2023; 13:1790. [PMID: 37763194 PMCID: PMC10532541 DOI: 10.3390/life13091790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 08/01/2023] [Accepted: 08/19/2023] [Indexed: 09/29/2023] Open
Abstract
Aging is an inevitable process that impacts the peripheral and central nervous systems and is considered one of the strongest risk factors for neurodegenerative diseases. In addition, when it also presents with diabetes mellitus, the risk of neurological damage may be further increased. This current study aimed to explore the relationships between peripheral sensory system decline and cognitive functions, the symptoms of depression, and quality of life (QoL) as metrics of central nervous system impairment in institutionalized older adults. A total of 95 individuals participated in this case-control study, which included diabetics and non-diabetics. The superficial sensory pathway was assessed in terms of thermal sensation, nociception, and non-discriminative touch, and the deep sensory pathway was evaluated by assessing vibration and light touch-pressure sensations. To assess function at the intellectual level, the Mini-Mental State Examination (MMSE) and Trail Making Test (TMT) cognitive functional tests were used, while the symptoms of depression and QoL were explored by employing the Yesavage Geriatric Depression Scale and EuroQol 5D questionnaire (EQ-5D), respectively. In the overall population analyses, altered thermal sensation was significantly associated with cognitive impairment (CI; p < 0.05). In turn, bivariate analyses and a binary logistic regression showed that the symptoms of depression and QoL were significantly related to altered vibratory sensation when assessed using a medical tuning fork (p < 0.05). In the group of diabetic patients, those with CI also had significantly lower thermal sensation (p < 0.05) and non-discriminative touch sensation, although this was only a trend (p = 0.055). Diabetics with depression had a significantly worse non-discriminative touch (p < 0.05) and vibratory sensation when tested with a tuning fork (p < 0.05). In addition, poorer QoL was associated with reduced sensitivity to heat (p < 0.05), light touch pressure (p < 0.05), and vibrations when assessed either with a tuning fork (p < 0.05) or a biothesiometer (p < 0.05). In contrast, no relationships were found between sensory functions and cognitive assessments in non-diabetic patients. These findings indicate that superficial sensitivity damage was related to CI, while deep sensation alterations were related to depression and poor QoL, with diabetes apparently further strengthening these relationships.
Collapse
Affiliation(s)
- Mar Sempere-Bigorra
- Department of Nursing, Faculty of Nursing and Podiatry, University of Valencia, 46010 Valencia, Spain; (M.S.-B.); (I.J.-R.); (P.P.-R.); (E.N.-F.)
- Frailty Research Organized Group (FROG), Department of Nursing, University of Valencia, 46010 Valencia, Spain;
| | - Iván Julián-Rochina
- Department of Nursing, Faculty of Nursing and Podiatry, University of Valencia, 46010 Valencia, Spain; (M.S.-B.); (I.J.-R.); (P.P.-R.); (E.N.-F.)
- Frailty Research Organized Group (FROG), Department of Nursing, University of Valencia, 46010 Valencia, Spain;
| | - Pilar Pérez-Ros
- Department of Nursing, Faculty of Nursing and Podiatry, University of Valencia, 46010 Valencia, Spain; (M.S.-B.); (I.J.-R.); (P.P.-R.); (E.N.-F.)
- Frailty Research Organized Group (FROG), Department of Nursing, University of Valencia, 46010 Valencia, Spain;
| | - Emmanuel Navarro-Flores
- Department of Nursing, Faculty of Nursing and Podiatry, University of Valencia, 46010 Valencia, Spain; (M.S.-B.); (I.J.-R.); (P.P.-R.); (E.N.-F.)
- Frailty Research Organized Group (FROG), Department of Nursing, University of Valencia, 46010 Valencia, Spain;
| | - Francisco Miguel Martínez-Arnau
- Frailty Research Organized Group (FROG), Department of Nursing, University of Valencia, 46010 Valencia, Spain;
- Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain
| | - Omar Cauli
- Department of Nursing, Faculty of Nursing and Podiatry, University of Valencia, 46010 Valencia, Spain; (M.S.-B.); (I.J.-R.); (P.P.-R.); (E.N.-F.)
- Frailty Research Organized Group (FROG), Department of Nursing, University of Valencia, 46010 Valencia, Spain;
| |
Collapse
|
10
|
Karami F, Jamaati H, Coleman-Fuller N, Zeini MS, Hayes AW, Gholami M, Salehirad M, Darabi M, Motaghinejad M. Is metformin neuroprotective against diabetes mellitus-induced neurodegeneration? An updated graphical review of molecular basis. Pharmacol Rep 2023; 75:511-543. [PMID: 37093496 DOI: 10.1007/s43440-023-00469-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 02/21/2023] [Accepted: 02/23/2023] [Indexed: 04/25/2023]
Abstract
Diabetes mellitus (DM) is a metabolic disease that activates several molecular pathways involved in neurodegenerative disorders. Metformin, an anti-hyperglycemic drug used for treating DM, has the potential to exert a significant neuroprotective role against the detrimental effects of DM. This review discusses recent clinical and laboratory studies investigating the neuroprotective properties of metformin against DM-induced neurodegeneration and the roles of various molecular pathways, including mitochondrial dysfunction, oxidative stress, inflammation, apoptosis, and its related cascades. A literature search was conducted from January 2000 to December 2022 using multiple databases including Web of Science, Wiley, Springer, PubMed, Elsevier Science Direct, Google Scholar, the Core Collection, Scopus, and the Cochrane Library to collect and evaluate peer-reviewed literature regarding the neuroprotective role of metformin against DM-induced neurodegenerative events. The literature search supports the conclusion that metformin is neuroprotective against DM-induced neuronal cell degeneration in both peripheral and central nervous systems, and this effect is likely mediated via modulation of oxidative stress, inflammation, and cell death pathways.
Collapse
Affiliation(s)
- Fatemeh Karami
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Hamidreza Jamaati
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Natalie Coleman-Fuller
- Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, 55108, USA
| | - Maryam Shokrian Zeini
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - A Wallace Hayes
- University of South Florida College of Public Health and Institute for Integrative Toxicology, Michigan State University, East Lansing, USA
| | - Mina Gholami
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahsa Salehirad
- Cognitive and Neuroscience Research Center (CNRC), Amir-Almomenin Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Mohammad Darabi
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Majid Motaghinejad
- Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
11
|
Xu L, Xiong Q, Du Y, Huang LW, Yu M. Nonlinear relationship between glycated hemoglobin and cognitive impairment after acute mild ischemic stroke. BMC Neurol 2023; 23:116. [PMID: 36949414 PMCID: PMC10031995 DOI: 10.1186/s12883-023-03158-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Accepted: 03/11/2023] [Indexed: 03/24/2023] Open
Abstract
BACKGROUND Stroke is the second most common cause of morbidity and mortality. Even mild stroke survivors have an increased risk of cognitive impairment. Studies have been conducted on the relationship between glycated hemoglobin (HbA1c) and cognitive decline, but the findings have been inconsistent. Therefore, this study examined the link between HbA1c levels and cognitive impairment following acute mild ischemic stroke. METHODS Data from 311 patients with acute mild ischemic stroke admitted to Suining Central Hospital, Sichuan Province, China, from January 1, 2015, to December 31, 2018, were evaluated. Fasting venous blood was taken to assess HbA1c levels on the day after admission. Cognitive function was assessed using the Chinese version of the Montreal Cognitive Assessment Scale (MoCA) 3-6 months after stroke onset. We used a generalized additive model and smooth curve fitting (penalty spline method) to assess the nonlinear relationship between HbA1c and poststroke cognitive impairment (PSCI). RESULTS This study included 311 patients aged 23 to 96 years old (mean age: 67.37 ± 11.92 years), of whom 198 (63.67%) were men. Among the 311 stroke patients, 120 (38.59%) had PSCI. After adjusting for potential confounders, there was a nonlinear relationship between HbA1c and PSCI, with an inflection point of 8.2. To the left of the inflection point, the effect size, 95% confidence interval, and P value were 0.87, 0.58 to 1.31, and 0.5095, respectively; however, to the right of the inflection point, these numbers were 1.96, 1.08 to 3.58, and 0.0280. CONCLUSION We found a nonlinear relationship between HbA1c and PSCI. When HbA1c was greater than 8.2%, HbA1c was positively correlated with PSCI.
Collapse
Affiliation(s)
- Lei Xu
- Department of Neurology, Suining Central Hospital, Suining, 629000, China
| | - Qin Xiong
- Department of Internal Medicine, the Third People's Hospital of Suining, Suining, 629000, China
| | - Yang Du
- Department of Neurology, Suining Central Hospital, Suining, 629000, China
| | - Lu-Wen Huang
- Department of Neurology, Suining Central Hospital, Suining, 629000, China
| | - Ming Yu
- Department of Neurology, Suining Central Hospital, Suining, 629000, China.
| |
Collapse
|
12
|
Parsons RF, Tantisattamo E, Cheungpasitporn W, Basu A, Lu Y, Lentine KL, Woodside KJ, Singh N, Scalea J, Alhamad T, Dunn TB, Rivera FHC, Parajuli S, Pavlakis M, Cooper M. Comprehensive review: Frailty in pancreas transplant candidates and recipients. Clin Transplant 2023; 37:e14899. [PMID: 36591953 DOI: 10.1111/ctr.14899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 12/22/2022] [Accepted: 12/29/2022] [Indexed: 01/03/2023]
Abstract
Well-selected patients with kidney disease and diabetes mellitus who undergo simultaneous kidney-pancreas transplantation often experience dramatic improvements in quality of life and long-term survival compared to those who remain on medical therapy. Over the past several years the importance of frailty in the pancreas transplant candidate and recipient populations has grown. More patients with advanced age have entered the waitlist, and complications from prolonged diabetes, even in younger patients, have created increased evidence of risk for frailty. Given these concerns, and the broad challenges facing pancreas transplantation volumes overall, we generated this review to help establish the impact and implications. We summarize the interplay of immunological factors, aging, environmental factors, diabetes mellitus, and chronic kidney disease that put these patients at risk for frailty. We discuss its measurement and recommend a combination of two instruments (both well-validated and one entirely objective). We describe the outcomes for patients before and after pancreas transplantation who may have frailty, and what interventions can be taken to mitigate its effects. Broader investigation into frailty in the pancreas transplant population is needed to better understand how to select patients for pancreas transplantation and to how manage its consequences thereafter.
Collapse
Affiliation(s)
| | | | | | | | - Yee Lu
- University of Michigan, Ann Arbor, Michigan, USA
| | | | | | - Neeraj Singh
- John C. McDonald Regional Transplant Center, Shreveport, Los Angeles, USA
| | - Joseph Scalea
- Medical University of South Carolina, Charleston, South Carolina, USA
| | - Tarek Alhamad
- Washington University School of Medicine, St. Louis, Missouri, USA
| | - Ty B Dunn
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | | | - Martha Pavlakis
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Matthew Cooper
- Medstar Georgetown Transplant Institute, Washington DC, USA
| |
Collapse
|
13
|
Zhao D, Huang Y, Wang B, Chen H, Pan W, Yang M, Xia Z, Zhang R, Yuan C. Dietary Intake Levels of Iron, Copper, Zinc, and Manganese in Relation to Cognitive Function: A Cross-Sectional Study. Nutrients 2023; 15:nu15030704. [PMID: 36771411 PMCID: PMC9921562 DOI: 10.3390/nu15030704] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 01/25/2023] [Accepted: 01/27/2023] [Indexed: 02/01/2023] Open
Abstract
Background: Previous studies have related circulating levels of trace metal elements, of which dietary intake is the major source, to cognitive outcomes. However, there are still relatively few studies evaluating the associations of dietary intake levels of iron, copper, zinc, and manganese with cognitive function (CF). Methods: We leveraged the data of 6863 participants (mean [standard deviation] age = 66.7 [10.5] years) in the Health and Retirement Study (2013/2014). Dietary intake levels of iron, copper, zinc, and manganese were calculated from a semi-quantitative food frequency questionnaire. CF was assessed using the 27-point modified Telephone Interview for Cognitive Status (TICS). We used linear regression models to calculate the mean differences in global CF scores by quintiles of dietary intake levels of trace metal elements. Results: Among the study participants, the mean (SD) values of daily dietary intake were 13.3 (6.3) mg for iron, 1.4 (0.7) mg for copper, 10.7 (4.6) mg for zinc, and 3.3 (1.6) mg for manganese. Compared with the lowest quintile of dietary iron intake (<8.1 mg), the highest quintile (≥17.7 mg) was associated with a lower cognitive score (-0.50, -0.94 to -0.06, P-trend = 0.007). Higher dietary copper was significantly associated with poorer CF (P-trend = 0.002), and the mean difference in cognitive score between extreme quintiles (≥1.8 vs. <0.8 mg) was -0.52 (95% confidence interval: -0.94 to -0.10) points. We did not observe significant associations for dietary intake of zinc (P-trend = 0.785) and manganese (P-trend = 0.368). Conclusion: In this cross-sectional study, higher dietary intake of iron and copper was related to worse CF, but zinc and manganese intake levels were not significantly associated with CF.
Collapse
Affiliation(s)
- Dong Zhao
- Department of Nutrition and Food Safety, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China
| | - Yilun Huang
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
- College of Biosystem Engineering and Food Science, Zhejiang University, Hangzhou 310051, China
| | - Binghan Wang
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
| | - Hui Chen
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
| | - Wenfei Pan
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
| | - Min Yang
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
| | - Zhidan Xia
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
| | - Ronghua Zhang
- Department of Nutrition and Food Safety, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China
- Correspondence: (R.Z.); (C.Y.)
| | - Changzheng Yuan
- School of Public Health, Zhejiang University School of Medicine, Hangzhou 310051, China
- Correspondence: (R.Z.); (C.Y.)
| |
Collapse
|
14
|
Liu G, Li Y, Xu Y, Li W. Type 2 diabetes is associated with increased risk of dementia, but not mild cognitive impairment: a cross-sectional study among the elderly in Chinese communities. Front Aging Neurosci 2022; 14:1004954. [PMID: 36185492 PMCID: PMC9524142 DOI: 10.3389/fnagi.2022.1004954] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 08/29/2022] [Indexed: 11/13/2022] Open
Abstract
Background: Previous studies have confirmed that diabetes is associated with cognitive impairment, but there is little data on this among older Chinese. Methods: This study included 192 dementia patients, 610 patients with mild cognitive impairment (MCI), and 2,218 normal controls. Their general demographic information (such as gender, age, education, etc.), disease-related information (hypertension), and diabetes information (such as whether you have diabetes, course of the disease, etc) were collected by standardized questionnaires. The mini-mental state examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess their overall cognitive function, Moreover, 84 healthy, randomly selected older adults also underwent brain MRI scans at the same time, and the target brain regions included the hippocampus, the third, fourth, and fifth ventricles. Results: The proportion of type 2 diabetes was significantly higher in the dementia group (25.5%) than that in the normal elderly group (15.6%) and the MCI group (17.7%). By using stepwise multiple logistics regression analysis, we found that type 2 diabetes was associated with dementia (p = 0.005*, OR = 1.805, 95%CI: 1.199-2.761), but not with MCI (p > 0.05). The volume of the fourth ventricle of the healthy elderly with diabetes was significantly larger than that of the healthy elderly without diabetes (p < 0.05), but there was no statistical difference (p > 0.05) in the volume of the hippocampus, the third ventricle, and the fifth ventricle between the two groups. However, we did not find an association between the fourth ventricle and cognitive scores (MMSE and MoCA). Conclusions: In conclusion, type 2 diabetes in elderly Chinese people is associated with dementia, but not MCI. Type 2 diabetes may impair cognitive function by affecting the volume of the fourth ventricle. However, larger longitudinal follow-up studies are needed to confirm these conclusions.
Collapse
Affiliation(s)
- Guojun Liu
- Department of Rehabilitation Medicine, The Third People’s Hospital of Lanzhou, Lanzhou, China
| | - Yong Li
- Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China
- Department of Nephrology, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China
- Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, China
| | - Yuzhen Xu
- Department of Rehabilitation, The Second Affiliated Hospital of Shandong First Medical University, Taian, China
| | - Wei Li
- Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China
| |
Collapse
|
15
|
Margrett JA, Schofield T, Martin P, Poon LW, Masaki K, Donlon TA, Kallianpur KJ, Willcox BJ. Novel Functional, Health, and Genetic Determinants of Cognitive Terminal Decline: Kuakini Honolulu Heart Program/Honolulu-Asia Aging Study. J Gerontol A Biol Sci Med Sci 2022; 77:1525-1533. [PMID: 34918073 PMCID: PMC9373950 DOI: 10.1093/gerona/glab327] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Indexed: 11/13/2022] Open
Abstract
To investigate interindividual differences in cognitive terminal decline and identify determinants including functional, health, and genetic risk and protective factors, data from the Honolulu Heart Program/Honolulu-Asia Aging Study, a prospective cohort study of Japanese American men, were analyzed. The sample was recruited in 1965-1968 (ages 45-68 years). Longitudinal performance of cognitive abilities and mortality status were assessed from Exam 4 (1991-1993) through June 2014. Latent class analysis revealed 2 groups: maintainers retained relatively high levels of cognitive functioning until death and decliners demonstrated significant cognitive waning several years prior to death. Maintainers were more likely to have greater education, diagnosed coronary heart disease, and presence of the apolipoprotein E (APOE) ε2 allele and FOXO3 G allele (SNP rs2802292). Decliners were more likely to be older and have prior stroke, Parkinson's disease, dementia, and greater depressive symptoms at Exam 4, and the APOE ε4 allele. Findings support terminal decline using distance to death as the basis for modeling change. Significant differences were observed between maintainers and decliners 15 years prior to death, a finding much earlier compared to the majority of previous investigations.
Collapse
Affiliation(s)
- Jennifer A Margrett
- Department of Human Development and Family Studies, College of Human Sciences, Iowa State University, Ames, Iowa, USA
| | - Thomas Schofield
- Department of Human Development and Family Studies, College of Human Sciences, Iowa State University, Ames, Iowa, USA
| | - Peter Martin
- Department of Human Development and Family Studies, College of Human Sciences, Iowa State University, Ames, Iowa, USA
| | - Leonard W Poon
- Institute of Gerontology, University of Georgia, Athens, Georgia, USA
| | - Kamal Masaki
- Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
- Department of Research, Kuakini Medical Center, Honolulu, Hawaii, USA
| | - Timothy A Donlon
- Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
- Department of Research, Kuakini Medical Center, Honolulu, Hawaii, USA
| | - Kalpana J Kallianpur
- Department of Research, Kuakini Medical Center, Honolulu, Hawaii, USA
- Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
| | - Bradley J Willcox
- Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
- Department of Research, Kuakini Medical Center, Honolulu, Hawaii, USA
| |
Collapse
|
16
|
Tadevosyan NE, Khachunts AS, Gohargani M, Sahakyan AA, Tumanyan AA. Voluntary Attention and Quality of Life in Patients With Type 1 and Type 2 Diabetes Mellitus: Differences in Changes Depending on Disease Type and Duration. J EVOL BIOCHEM PHYS+ 2022. [DOI: 10.1134/s0022093022020247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
17
|
Piątkowska-Chmiel I, Gawrońska-Grzywacz M, Popiołek Ł, Herbet M, Dudka J. The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment. Sci Rep 2022; 12:6708. [PMID: 35468904 PMCID: PMC9035983 DOI: 10.1038/s41598-022-10187-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 03/14/2022] [Indexed: 12/12/2022] Open
Abstract
Diabetes is a chronic disease leading to memory difficulties and deterioration of learning abilities. The previous studies showed that modulation of inflammatory pathways in the diabetic brain may reduce dysfunction or cell death in brain areas which are important for control of cognitive function. In the present study, we investigated the neuroprotective actions of newly synthesized adamantane derivatives on diabetes-induced cognitive impairment in mice. Our study relied on the fact that both vildagliptin and saxagliptin belong to DPP4 inhibitors and, contain adamantanyl group. Efficacy of tested compounds at reversing diabetes-induced different types of memory impairment was evaluated with the use of selected behavioural tests. The following neuroinflammatory indicators were also analyzed: neuroinflammatory indicators and the expression of genes involved in the inflammatory response of brain (Cav1, Bdnf). Our study demonstrated that new adamantane derivatives, similarly to DPP4 inhibitors, can restrict diabetes-induced cognitive deficits. We demonstrated that the overexpression of GLP-1-glucagon-like peptide as well as Bdnf, Cav1 genes translate into central blockade of pro-inflammatory synthesis of cytokines and significantly improvement on memory performance in diabetes mice. Newly synthesized adamantane derivatives might have important roles in prevention and treatment of cognitive impairment by inflammatory events in patients with diabetes or related diseases.
Collapse
Affiliation(s)
- Iwona Piątkowska-Chmiel
- Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland.
| | - Monika Gawrońska-Grzywacz
- Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland
| | - Łukasz Popiołek
- Chair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki Street, 20-093, Lublin, Poland
| | - Mariola Herbet
- Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland
| | - Jarosław Dudka
- Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland
| |
Collapse
|
18
|
Fan YC, Chou CC, Bintoro BS, Pan WH, Bai CH. Combined Effect of Inflammation and Hyperglycemia on Mild Cognitive Impairment and Associated Dietary Patterns in an Older Taiwanese Population. Front Nutr 2022; 9:791929. [PMID: 35252292 PMCID: PMC8895042 DOI: 10.3389/fnut.2022.791929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2021] [Accepted: 01/20/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundPrevious studies have demonstrated that C-reactive protein (CRP) and glycated hemoglobin (HbA1c) levels are independently associated with neurodegenerative diseases, which can be improved by altering dietary patterns. This study investigates the combined effect of CRP and HbA1c, as well as the influence of dietary patterns, on the risk of dementia.MethodsA cross-sectional study was conducted with 536 participants aged ≥65 years who were recruited from the Nutrition and Health Survey in Taiwan between 2014 and 2016. The high levels of inflammation and glycation were defined as a CRP level of >0.21 mg/dl and a HbA1c level of ≥6.50%, respectively. Mild cognitive impairment (MCI) was evaluated using the Mini-Mental State Examination (MMSE) score. The dietary patterns associated with CRP and HbA1c levels were assessed using the reduced rank regression (RRR). Multivariate logistic regression analysis of both complete and imputed datasets was performed.ResultsParticipants with high levels of both CRP and HbA1c were associated with the highest odds ratio (OR) of MCI (adjusted OR [aOR] = 3.52; 95% CI = 3.48, 3.56; p < 0.001), followed by a high level of only HbA1c (aOR = 1.73; p < 0.001) and a high level of CRP (aOR = 1.49; p < 0.001). Using the reduced rank regression, an inverse relationship between higher consumption nuts and seeds and lower levels of CRP and HbA1c was found (both factors loading < −0.2). Concerning the combined effect of tertiles among the factor 1 and factor 2 analyzed by dietary patterns, group 1 with both T3 (high tertiles) was associated with the greatest OR of MCI (aOR = 4.38; 95% CI = 4.34, 4.42; p < 0.001) using multiple imputation.ConclusionsThe combined effect of high levels of inflammation and hyperglycemia was associated with an increased likelihood of MCI. Moreover, dietary patterns positively related to inflammation and hyperglycemia were associated with MCI, while eating nuts and seeds promoted better cognition.
Collapse
Affiliation(s)
- Yen-Chun Fan
- School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan
| | - Chia-Chi Chou
- Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan
- School of Medicine, Chang Gung University, Taoyuan, Taiwan
- Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan
| | - Bagas Suryo Bintoro
- International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Department of Health Behavior, Environment, and Social Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
- Center of Health Behavior and Promotion, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Wen-Harn Pan
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Chyi-Huey Bai
- School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan
- Department of Public Health, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Nutrition Research Center, Taipei Medical University Hospital, Taipei, Taiwan
- *Correspondence: Chyi-Huey Bai
| |
Collapse
|
19
|
Eastman JA, Kaup AR, Bahorik AL, Butcher X, Attarha M, Marcus GM, Pletcher MJ, Olgin JE, Barnes DE, Yaffe K. Remote Assessment of Cardiovascular Risk Factors and Cognition in Middle-Aged and Older Adults: Proof-of-Concept Study. JMIR Form Res 2022; 6:e30410. [PMID: 35107430 PMCID: PMC8851369 DOI: 10.2196/30410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 12/08/2021] [Indexed: 11/25/2022] Open
Abstract
Background Adults with cardiovascular disease risk factors (CVRFs) are also at increased risk of developing cognitive decline and dementia. However, it is often difficult to study the relationships between CVRFs and cognitive function because cognitive assessment typically requires time-consuming in-person neuropsychological evaluations that may not be feasible for real-world situations. Objective We conducted a proof-of-concept study to determine if the association between CVRFs and cognitive function could be detected using web-based, self-administered cognitive tasks and CVRF assessment. Methods We recruited 239 participants aged ≥50 years (mean age 62.7 years, SD 8.8; 42.7% [n=102] female, 88.7% [n=212] White) who were enrolled in the Health eHeart Study, a web-based platform focused on cardiac disease. The participants self-reported CVRFs (hypertension, high cholesterol, diabetes, and atrial fibrillation) using web-based health surveys between August 2016 and July 2018. After an average of 3 years of follow-up, we remotely evaluated episodic memory, working memory, and executive function via the web-based Posit Science platform, BrainHQ. Raw data were normalized and averaged into 3 domain scores. We used linear regression models to examine the association between CVRFs and cognitive function. Results CVRF prevalence was 62.8% (n=150) for high cholesterol, 45.2% (n=108) for hypertension, 10.9% (n=26) for atrial fibrillation, and 7.5% (n=18) for diabetes. In multivariable models, atrial fibrillation was associated with worse working memory (β=-.51, 95% CI -0.91 to -0.11) and worse episodic memory (β=-.31, 95% CI -0.59 to -0.04); hypertension was associated with worse episodic memory (β=-.27, 95% CI -0.44 to -0.11). Diabetes and high cholesterol were not associated with cognitive performance. Conclusions Self-administered web-based tools can be used to detect both CVRFs and cognitive health. We observed that atrial fibrillation and hypertension were associated with worse cognitive function even in those in their 60s and 70s. The potential of mobile assessments to detect risk factors for cognitive aging merits further investigation.
Collapse
Affiliation(s)
- Jennifer A Eastman
- San Francisco VA Medical Center, San Francisco, CA, United States.,Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States
| | - Allison R Kaup
- San Francisco VA Medical Center, San Francisco, CA, United States.,Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States.,The Neurology Center of Southern California, Carlsbad, CA, United States
| | - Amber L Bahorik
- Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States
| | - Xochitl Butcher
- Department of Medicine, University of California, San Francisco, CA, United States
| | - Mouna Attarha
- Posit Science Corporation, San Francisco, CA, United States
| | - Gregory M Marcus
- Department of Medicine, University of California, San Francisco, CA, United States
| | - Mark J Pletcher
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States
| | - Jeffrey E Olgin
- Department of Medicine, University of California, San Francisco, CA, United States
| | - Deborah E Barnes
- San Francisco VA Medical Center, San Francisco, CA, United States.,Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States.,Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States
| | - Kristine Yaffe
- San Francisco VA Medical Center, San Francisco, CA, United States.,Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States.,Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States.,Department of Neurology, University of California, San Francisco, CA, United States
| |
Collapse
|
20
|
Bashir J, Yarube IU. Occurrence of mild cognitive impairment with hyperinsulinaemia in Africans with advanced type 2 diabetes mellitus. IBRO Neurosci Rep 2022; 12:182-187. [PMID: 35746970 PMCID: PMC9210459 DOI: 10.1016/j.ibneur.2022.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 02/09/2022] [Indexed: 11/08/2022] Open
Abstract
There is paucity of information on the prevalence of mild cognitive impairment (MCI) among individuals with type 2 diabetes mellitus (T2DM) in sub-Saharan Africa, including Nigeria. In addition, the role of hyperinsulinaemia in the development of MCI needs further investigation. This study sought to assess cognition and hyperinsulinaemia, with the associated characteristics in patients with advanced T2DM. Cognition was assessed using Montreal cognitive assessment test (MoCA), while fasting plasma insulin was measured using an ELISA kit. Sixty one diabetic subjects and 32 non-diabetic controls, matched for age, gender and level of education were studied. The diabetics had MCI while the controls had normal cognitive function. About 88.5% of the diabetic subjects had MCI, in contrast with only 50% of the non-diabetic controls. The most significantly affected cognitive domains among the diabetics were executive function, naming, attention, abstraction and delayed recall. Among the diabetics, MCI correlated with age, weight and body mass index (BMI); and in addition, age and weight found to be significant predictors of MCI. Plasma insulin concentration among the diabetics (16.24 ± 13.5 µIU/ml) was more than twice that of the controls (7.59 ± 2.9 µIU/ml). Hyperinsulinaemia among the diabetics correlated with weight, BMI, blood pressure and fasting blood sugar (FBS). Glycated haemoglobin and FBS levels were higher among diabetics compared with the controls. In conclusion, Africans with advanced T2DM show multi-domain MCI with high prevalence, coexisting with hyperinsulinaemia. Majority of the patients have diabetic complications and poor glycaemic control. Hyperinsulinaemia may play a complementary role in the pathophysiology of MCI in T2DM. Patients with advanced T2DM manifest multi-domain MCI with up to 88% prevalence. There is hyperinsulinaemia coexisting with the MCI among patients with advanced 2DM. Majority of the patients have diabetic complications and poor glycaemic control.
Collapse
|
21
|
Wang S, Jiao F, Border JJ, Fang X, Crumpler RF, Liu Y, Zhang H, Jefferson J, Guo Y, Elliott PS, Thomas KN, Strong LB, Urvina AH, Zheng B, Rijal A, Smith SV, Yu H, Roman RJ, Fan F. Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals. Am J Physiol Heart Circ Physiol 2022; 322:H246-H259. [PMID: 34951541 PMCID: PMC8759958 DOI: 10.1152/ajpheart.00438.2021] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 11/29/2021] [Accepted: 12/15/2021] [Indexed: 02/03/2023]
Abstract
Diabetes mellitus (DM) is a leading risk factor for age-related dementia, but the mechanisms involved are not well understood. We previously discovered that hyperglycemia induced impaired myogenic response (MR) and cerebral blood flow (CBF) autoregulation in 18-mo-old DM rats associated with blood-brain barrier (BBB) leakage, impaired neurovascular coupling, and cognitive impairment. In the present study, we examined whether reducing plasma glucose with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) luseogliflozin can ameliorate cerebral vascular and cognitive function in diabetic rats. Plasma glucose and HbA1c levels of 18-mo-old DM rats were reduced, and blood pressure was not altered after treatment with luseogliflozin. SGLT2i treatment restored the impaired MR of middle cerebral arteries (MCAs) and parenchymal arterioles and surface and deep cortical CBF autoregulation in DM rats. Luseogliflozin treatment also rescued neurovascular uncoupling, reduced BBB leakage and cognitive deficits in DM rats. However, SGLT2i did not have direct constrictive effects on vascular smooth muscle cells and MCAs isolated from normal rats, although it decreased reactive oxygen species production in cerebral vessels of DM rats. These results provide evidence that normalization of hyperglycemia with an SGLT2i can reverse cerebrovascular dysfunction and cognitive impairments in rats with long-standing hyperglycemia, possibly by ameliorating oxidative stress-caused vascular damage.NEW & NOTEWORTHY This study demonstrates that luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, improved CBF autoregulation in association with reduced vascular oxidative stress and AGEs production in the cerebrovasculature of 18-mo-old DM rats. SGLT2i also prevented BBB leakage, impaired functional hyperemia, neurodegeneration, and cognitive impairment seen in DM rats. Luseogliflozin did not have direct constrictive effects on VSMCs and MCAs isolated from normal rats. These results provide evidence that normalization of hyperglycemia with an SGLT2i can reverse cerebrovascular dysfunction and cognitive impairments in rats with long-standing hyperglycemia, possibly by ameliorating oxidative stress-caused vascular damage.
Collapse
Affiliation(s)
- Shaoxun Wang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Feng Jiao
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Jane J Border
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Xing Fang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Reece F Crumpler
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Yedan Liu
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Huawei Zhang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Joshua Jefferson
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Ya Guo
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Parker S Elliott
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Kirby N Thomas
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Luke B Strong
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Austin H Urvina
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Baoying Zheng
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Arjun Rijal
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Stanley V Smith
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Hongwei Yu
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Richard J Roman
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Fan Fan
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| |
Collapse
|
22
|
Vaughan Dickson V, Melnyk H, Ferris R, Leon A, Arcila-Mesa M, Rapozo C, Chodosh J, Blaum CS. Perceptions of Treatment Burden Among Caregivers of Elders With Diabetes and Co-morbid Alzheimer's Disease and Related Dementias: A Qualitative Study. Clin Nurs Res 2022; 32:752-758. [PMID: 34991360 DOI: 10.1177/10547738211067880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Many older adults with diabetes (DM) have co-occurring Alzheimer's Disease (AD) and AD-Related Dementias (ADRD). Complex treatment plans may impose treatment burden for caregivers responsible for day-to-day self-management. The purpose of this qualitative study was to describe caregiver perceptions of treatment burden for people with DM-AD/ADRD. Caregivers (n = 33) of patients with DM-AD/ADRD participated in semi-structured interviews about their caregiver role and perceptions of treatment burden of DM-AD/ADRD management. Qualitative data were analyzed using content analysis (ATLAS.ti). Caregivers reported high levels of burden related to complex treatment/self-management for patients with DM-AD/ADRD that varied day-to-day with the patient's cognitive status. Four themes were: (1) trajectory of treatment burden; (2) navigating multiple healthcare providers/systems of care; (3) caregiver role conflict; and (4) emotional burden. Interventions to reduce caregiver treatment burden should include activating supportive services, education, and care coordination especially, if patient treatment increases in complexity over time.
Collapse
Affiliation(s)
| | - Halia Melnyk
- NYU Rory Meyers College of Nursing, New York, NY, USA
| | - Rosie Ferris
- NYU Grossman School of Medicine, New York, NY, USA
| | - Alejandra Leon
- Boston College Connell School of Nursing, Chestnut Hill, MA, USA
| | | | | | | | | |
Collapse
|
23
|
Samoilova IG, Matveeva MV, Kudlay DA, Tonkikh OS, Tolmachev IV. Neural networks in the predictive diagnosis of cognitive impairment in type 1 and type 2 diabetes mellitus. TERAPEVT ARKH 2021; 93:1349-1358. [DOI: 10.26442/00403660.2021.11.201253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 01/27/2022] [Indexed: 11/22/2022]
Abstract
Background. Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as a serious complication of diabetes mellitus (DM) that affects patient well-being and disease management. Magnetic resonance imaging (MRI)-studies have shown varying degrees of cortical atrophy, cerebral infarcts, and deep white matter lesions. To explain the relationship between DM and cognitive decline, several hypotheses have been proposed, based on the variability of glycemia leading to morphometric changes in the brain. The ability to predict cognitive decline even before its clinical development will allow the early prevention of this pathology, as well as to predict the course of the existing pathology and to adjust medication regimens.
Aim. To create a computer neural network model for predicting the development of cognitive impairment in DM on the basis of brain neuroimaging techniques.
Materials and methods. The study was performed in accordance with the standards of good clinical practice; the protocol was approved by the Ethics Committee. The study included 85 patients with type 1 diabetes and 95 patients with type 2 diabetes, who were divided into a group of patients with normal cognitive function and a group with cognitive impairment. The patient groups were comparable in age and duration of disease. Cognitive impairment was screened using the Montreal Cognitive Assessment Scale. Data for glycemic variability were obtained using continuous glucose monitoring (iPro2, Libre). A standard MRI scan of the brain was performed axially, sagittally, and coronally on a Signa Creator E, GE Healthcare, 1.5 Tesla, China. For MRI data processing we used Free Surfer program (USA) for analysis and visualization of structural and functional neuroimaging data from cross-sectional or longitudinal studies, and for segmentation we used Recon-all batch program directly. All statistical analyses and data processing were performed using Statistica Statsofi software (version 10) on Windows 7/XP Pro operating systems. The IBM WATSON cognitive system was used to build a neural network model.
Results. As a result of the study, cognitive impairment in DM type 1was predominantly of mild degree 36.9% (n=24) and moderate degree 30.76% (n=20), and in DM type 2 mild degree 37% (n=30), moderate degree 49.4% (n=40) and severe degree 13.6% (n=11). Cognitive functions in DM type 1 were impaired in memory and attention, whereas in DM type 2 they were also impaired in tasks of visual-constructive skills, fluency, and abstraction (p0.001). The analysis revealed differences in glycemic variability indices in patients with type 1 and type 2 DM and cognitive impairment. Standard MRI of the brain recorded the presence of white and gray matter changes (gliosis and leukoareosis). General and regional cerebral atrophy is characteristic of type 1 and type 2 DM, which is associated with dysglycemia. When building neural network models for type 1 diabetes, the parameters of decreased volumes of the brain regions determine the development of cognitive impairment by 93.5%, whereas additionally, the coefficients of glycemic variability by 98.5%. The same peculiarity was revealed in type 2 DM 95.3% and 97.9%, respectively.
Conclusion. In DM type 1 and type 2 with cognitive impairment, elevated coefficients of glycemic variability are more frequently recorded. This publication describes laboratory and instrumental parameters as potential diagnostic options for effective management of DM and prevention of cognitive impairment. Neural network models using glycemic variability coefficients and MR morphometry allow for predictive diagnosis of cognitive disorders in both types of diabetes.
Collapse
|
24
|
Frison E, Proust-Lima C, Mangin JF, Habert MO, Bombois S, Ousset PJ, Pasquier F, Hanon O, Paquet C, Gabelle A, Ceccaldi M, Annweiler C, Krolak-Salmon P, Béjot Y, Belin C, Wallon D, Sauvee M, Beaufils E, Bourdel-Marchasson I, Jalenques I, Chupin M, Chêne G, Dufouil C. Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort. Neurology 2021; 97:e836-e848. [PMID: 34210821 PMCID: PMC8397583 DOI: 10.1212/wnl.0000000000012440] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Accepted: 05/25/2021] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To assess the role of biomarkers of Alzheimer disease (AD), neurodegeneration, and small vessel disease (SVD) as mediators in the association between diabetes mellitus and cognition. METHODS The study sample was derived from MEMENTO, a cohort of French adults recruited in memory clinics and screened for either isolated subjective cognitive complaints or mild cognitive impairment. Diabetes was defined based on blood glucose assessment, use of antidiabetic agent, or self-report. We used structural equation modeling to assess whether latent variables of AD pathology (PET mean amyloid uptake, Aβ42/Aβ40 ratio, and CSF phosphorylated tau), SVD (white matter hyperintensities volume and visual grading), and neurodegeneration (mean cortical thickness, brain parenchymal fraction, hippocampal volume, and mean fluorodeoxyglucose uptake) mediate the association between diabetes and a latent variable of cognition (5 neuropsychological tests), adjusting for potential confounders. RESULTS There were 254 (11.1%) participants with diabetes among 2,288 participants (median age 71.6 years; 61.8% women). The association between diabetes and lower cognition was significantly mediated by higher neurodegeneration (standardized indirect effect: -0.061, 95% confidence interval: -0.089, -0.032), but not mediated by SVD and AD markers. Results were similar when considering latent variables of memory or executive functioning. CONCLUSION In a large clinical cohort in the elderly, diabetes is associated with lower cognition through neurodegeneration, independently of SVD and AD biomarkers.
Collapse
Affiliation(s)
- Eric Frison
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Cecile Proust-Lima
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Jean-Francois Mangin
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Marie-Odile Habert
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Stephanie Bombois
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Pierre-Jean Ousset
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Florence Pasquier
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Olivier Hanon
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Claire Paquet
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Audrey Gabelle
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Mathieu Ceccaldi
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Cédric Annweiler
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Pierre Krolak-Salmon
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Yannick Béjot
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Catherine Belin
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - David Wallon
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Mathilde Sauvee
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Emilie Beaufils
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Isabelle Bourdel-Marchasson
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Isabelle Jalenques
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Marie Chupin
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Geneviève Chêne
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Carole Dufouil
- From INSERM, UMR 1219 (E.F., C.P.-L., G.C., C.D.), and INSERM, CIC1401-EC (E.F., G.C., C.D.), Université de Bordeaux; Pole de Sante Publique Centre (E.F., G.C., C.D.) and Pole de Gérontologie Clinique (I.B.-M.), Hospitalier Universitaire (CHU) de Bordeaux; CATI Multicenter Neuroimaging Platform (J.-F.M., M.-O.H., M. Ceccaldi), Paris; Neurospin CEA Paris Saclay University (J.-F.M.), Gif-sur-Yvette; Laboratoire d'Imagerie Biomédicale (M.-O.H.), INSERM, CNRS, Sorbonne Université; Médecine Nucléaire (M.-O.H.), AP-HP, Hôpital Pitié-Salpêtrière; IM2A, AP-HP, INSERM, UMR-S975, Groupe Hospitalier, Pitié-Salpêtrière Institut de la Mémoire et de la Maladie d'Alzheimer (S.B.), and INSERM, U-1127, 3 CNRS, UMR 7225, CATI (M. Chupin), Institut du Cerveau et de la Moelle Épinière, Sorbonne Université, Paris; INSERM UMR1027 (P.-J.O.), Université de Toulouse III Paul Sabatier; Centre Mémoire (CMRR) Distalz (F.P.), CHU, INSERM 1171, Université de Lille; Service de Gériatrie (O.H.), Hôpital Broca, Université Paris Descartes; Centre de Neurologie (C.P.), INSERM U1144, Cognitive Hôpital Lariboisière, Université de Paris; Department of Neurology, INSERM U1061, Clinical and Research Memory Center of Montpellier (A.G.), Gui de Chauliac Hospital, University of Montpellier; Institut de Neurosciences des Systèmes, CMMR, PACA Ouest (M. Ceccaldi), INSERM, CHU Timone APHM and Aix Marseille Université; Department of Geriatric Medicine (C.A.), Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, Angers University Hospital, University of Angers, France; Department of Medical Biophysics (C.A.), Robarts Research Institute, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, Canada; Centre Mémoire Ressource et Recherche de Lyon (CMRR) (P.K.-S.), Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR5292, Hôpital des Charpennes, Hospices Civils de Lyon, Université de Lyon; Centre Mémoire de Ressources et de Recherches (Y.B.), CHU Dijon Bourgogne, EA7460, Université de Bourgogne, Dijon; Service de Neurologie Hôpital Saint-Louis AP-HP (C.B.), Paris; Departement de Neurologie (D.W.), UNIROUEN, INSERM U1245, CNR-MAJ, CHU de Rouen, Université de Normandie; CMRR Grenoble Arc Alpin (M.S.), CHU Grenoble; CMRR (E.B.), University Hospital Tours; Centre de Résonance Magnétique des Systèmes Biologiques (I.B.-M.), UMR 5536 Université de Bordeaux/CNRS; and Memory Resource and Research Centre of Clermont-Ferrand (I.J.), CHU de Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France.
| |
Collapse
|
25
|
Khan T, Khan S, Akhtar M, Ali J, Najmi AK. Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice. Neurochem Int 2021; 150:105158. [PMID: 34391818 DOI: 10.1016/j.neuint.2021.105158] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 08/05/2021] [Accepted: 08/10/2021] [Indexed: 01/21/2023]
Abstract
There is snowballing evidence that type 2 diabetes (T2D) predisposes to neuropathophysiological alterations including oxidative stress and triggered inflammatory responses in brain that eventually culminates into cognitive impairment.Accumulating evidences suggest that SGLT2 inhibitor can be a promising intervention for cognitive decline in T2DM. In the present paper, the potential effects of Empagliflozin (EMPA), a SGLT2 inhibitor, against T2D induced cognitive dysfunction have been explored. The effect of EMPA on array of inflammatory mediators including Interleukin-6(IL-6), Interleukin -1β (IL-1β), and Tumour necrosis factor-α(TNF-α)), neuronal proteins including glycogen synthase kinase-3β (GSK- 3β), Phosphorylated tau (p-tau), amyloid beta (Aβ) (1-40, 1-42) and altered oxidative parameters including SOD, catalase, TBARS was determined in the high fructose diet induced hyperglycaemic mice. The obtained results were compared with EMPA nanoparticles (Nps) formulated in our laboratory and found that EMPA Nps significantly showed reduced levels of inflammatory mediators and oxidative stress. Further, decrease in levels of p-tau, Aβ (1-40) and Aβ (1-42) were also observed with EMPA nanoparticles.Thus, the study has demonstrated that EMPA Nps could be a promising therapy to alleviate the progression of cognitive decline in T2D.
Collapse
Affiliation(s)
- Tahira Khan
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi, India
| | - Sana Khan
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi, India
| | - Mohd Akhtar
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi, India
| | - Javed Ali
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi, India
| | - Abul Kalam Najmi
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi, India.
| |
Collapse
|
26
|
Lin YJ, Kao TW, Chen WL. Relationship between peripheral neuropathy and cognitive performance in the elderly population. Medicine (Baltimore) 2021; 100:e26071. [PMID: 34011128 PMCID: PMC8137106 DOI: 10.1097/md.0000000000026071] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 04/07/2021] [Accepted: 04/27/2021] [Indexed: 01/05/2023] Open
Abstract
ABSTRACT There are only a few studies that have shown an association of peripheral neuropathy with cognitive impairment in elderly individuals. Therefore, we investigated the relationship between cognitive performance and peripheral neuropathy.From the database of the National Health and Nutrition Examination Survey (NHANES, 1999-2002), each participant completed a household interview, physical performance test, questionnaire regarding personal health, and Digit Symbol Substitution Test (DSST) to evaluate cognitive performance. The severity of peripheral neuropathy was assessed based on the number of insensate areas in both feet during monofilament examination. We used the multivariate linear regression to analyze the association of the DSST findings with insensate areas of the worse foot.There were 828 participants in our study from NHANES 1999 to 2002; their mean age was 69.96 ± 7.38 years, and 51.3% were male. The β coefficients of the number of insensate areas associated with the DSST findings were all negative values, and the absolute value increased as the number of insensate areas increased. After adjustment for pertinent variables, the correlations remained significantly negative (all P for trend <.001). In addition, subgroup analysis showed no gender differences in the negative association, but this association was not significant in obese participants (P > .05).Our study provides evidence that the severity of peripheral neuropathy is significantly negatively correlated with cognitive performance.
Collapse
Affiliation(s)
| | - Tung-Wei Kao
- Division of Family Medicine
- Division of Geriatric Medicine, School of Medicine, National Defense Medical Center
- Health Management Center, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei
| | - Wei-Liang Chen
- Division of Family Medicine
- Division of Geriatric Medicine, School of Medicine, National Defense Medical Center
- Health Management Center, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei
- Department of Biochemistry, National Defense Medical Center, Taiwan, Republic of China
| |
Collapse
|
27
|
Zhang X, Yu Y, Shi ZS, Xu K, Feng JH, Li ZY, Zhang XN, Shen SN, Yang Y, Yan LF, Zhang J, Sun Q, Hu B, Cui GB, Wang W. Increased resting state functional irregularity of T2DM brains with high HbA1c: sign for impaired verbal memory function? Brain Imaging Behav 2021; 15:772-781. [PMID: 32712796 DOI: 10.1007/s11682-020-00285-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Glycosylated hemoglobin A1c (HbA1c) has been considered as a key contributor to impaired cognition in type 2 diabetes mellitus (T2DM) brains. However, how does it affect the brain and whether the glucose controlling can slow down the process are still unknown. In the current study, T2DM patients with high glycosylated hemoglobin level (HGL) and controls with normal glycosylated hemoglobin level (NGL) were enrolled to investigate the relationships between HbA1c, brain imaging characteristics and cognitive function. First, a series of cognitive tests including California Verbal Learning Test (CVLT) were conducted. Then, the functional irregularity based on resting state functional magnetic resonance imaging data was evaluated via a new data-driven brain entropy (BEN) mapping analysis method. We found that the HGLs exhibited significantly increased BEN in the right precentral gyrus (PreCG.R), the right middle frontal gyrus (MFG.R), the triangular and opercular parts of the right inferior frontal gyrus (IFGtriang.R and IFGoperc.R). The strengths of the functional connections of PreCG.R with the brainstem/cerebellum were decreased. Partial correlation analysis showed that HbA1c had a strong positive correlation to regional BEN and negatively correlated with some CVLT scores. Negative correlations also existed between the BEN of PreCG.R/IFGoperc.R and some CVLT scores, suggesting the correspondence between higher HbA1c, increased BEN and decreased verbal memory function. This study demonstrated the potential of BEN in exploring the functional alterations affected by HbA1c and interpreting the verbal memory function decline. It will help understanding the neurophysiological mechanism of T2DM-induced cognitive decline and taking effective prevention or treatment measures.
Collapse
Affiliation(s)
- Xin Zhang
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
- Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, Shaanxi, China
| | - Ying Yu
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Zhe-Sheng Shi
- Student Brigade, Fourth Military Medical University, 169 Changle Road, Xi'an, 710032, Shaanxi, China
| | - Ke Xu
- Student Brigade, Fourth Military Medical University, 169 Changle Road, Xi'an, 710032, Shaanxi, China
| | - Jia-Hao Feng
- Student Brigade, Fourth Military Medical University, 169 Changle Road, Xi'an, 710032, Shaanxi, China
| | - Ze-Yang Li
- Student Brigade, Fourth Military Medical University, 169 Changle Road, Xi'an, 710032, Shaanxi, China
| | - Xiang-Nan Zhang
- Department of Science and Technology Affairs, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Shu-Ning Shen
- Department of Stomatology, PLA 984 Hospital, Beijing, 100094, China
| | - Yang Yang
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Lin-Feng Yan
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Jin Zhang
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Qian Sun
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Bo Hu
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China
| | - Guang-Bin Cui
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
| | - Wen Wang
- Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
| |
Collapse
|
28
|
Liu Y, Zhang H, Wang S, Guo Y, Fang X, Zheng B, Gao W, Yu H, Chen Z, Roman RJ, Fan F. Reduced pericyte and tight junction coverage in old diabetic rats are associated with hyperglycemia-induced cerebrovascular pericyte dysfunction. Am J Physiol Heart Circ Physiol 2021; 320:H549-H562. [PMID: 33306445 PMCID: PMC8082790 DOI: 10.1152/ajpheart.00726.2020] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 10/22/2020] [Accepted: 11/13/2020] [Indexed: 12/16/2022]
Abstract
Diabetes mellitus (DM) is one of the primary pathological factors that contributes to aging-related cognitive impairments, but the underlying mechanisms remain unclear. We recently reported that old DM rats exhibited impaired myogenic responses of the cerebral arteries and arterioles, poor cerebral blood flow autoregulation, enhanced blood-brain barrier (BBB) leakage, and cognitive impairments. These changes were associated with diminished vascular smooth muscle cell contractile capability linked to elevated reactive oxygen species (ROS) and reduced ATP production. In the present study, using a nonobese T2DN DM rat, we isolated parenchymal arterioles (PAs), cultured cerebral microvascular pericytes, and examined whether cerebrovascular pericyte in DM is damaged and whether pericyte dysfunction may play a role in the regulation of cerebral hemodynamics and BBB integrity. We found that ROS and mitochondrial superoxide production were elevated in PAs isolated from old DM rats and in high glucose (HG)-treated α-smooth muscle actin-positive pericytes. HG-treated pericytes displayed decreased contractile capability in association with diminished mitochondrial respiration and ATP production. Additionally, the expression of advanced glycation end products, transforming growth factor-β, vascular endothelial growth factor, and fibronectin were enhanced, but claudin 5 and integrin β1 was reduced in the brain of old DM rats and HG-treated pericytes. Further, endothelial tight junction and pericyte coverage on microvessels were reduced in the cortex of old DM rats. These results demonstrate our previous findings that the impaired cerebral hemodynamics and BBB leakage and cognitive impairments in the same old DM model are associated with hyperglycemia-induced cerebrovascular pericyte dysfunction.NEW & NOTEWORTHY This study demonstrates that the loss of contractile capability in pericytes in diabetes is associated with enhanced ROS and reduced ATP production. Enhanced advanced glycation end products (AGEs) in diabetes accompany with reduced pericyte and endothelial tight junction coverage in the cortical capillaries of old diabetic rats. These results suggest our previous findings that the impaired cerebral hemodynamics, BBB leakage, and cognitive impairments in old DM model are associated with hyperglycemia-induced cerebrovascular pericyte dysfunction.
Collapse
Affiliation(s)
- Yedan Liu
- Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Huawei Zhang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Shaoxun Wang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Ya Guo
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Xing Fang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Baoying Zheng
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Wenjun Gao
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Hongwei Yu
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Zongbo Chen
- Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Richard J Roman
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| | - Fan Fan
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi
| |
Collapse
|
29
|
Luo H, Tan C, Adhikari S, Plassman B, Kamer A, Sloan F, Schwartz M, Qi X, Wu B. Effects of the Co-occurrence of Diabetes Mellitus and Tooth Loss on Cognitive Function. Curr Alzheimer Res 2021; 18:1023-1031. [PMID: 34951384 PMCID: PMC8810293 DOI: 10.2174/1567205019666211223093057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 10/06/2021] [Accepted: 11/05/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Both diabetes mellitus (DM) and poor oral health are common chronic conditions and risk factors of Alzheimer's disease and related dementia among older adults. This study assessed the effects of DM and complete tooth loss (TL) on cognitive function, accounting for their interactions. METHODS Longitudinal data were obtained from the 2006, 2012, and 2018 waves of the Health and Retirement Study. This cohort study included 7,805 respondents aged 65 years or older with 18,331 person-year observations. DM and complete TL were self-reported. Cognitive function was measured by the Telephone Interview for Cognitive Status. Random-effect regressions were used to test the associations, overall and stratified by sex. RESULTS Compared with older adults without neither DM nor complete TL, those with both conditions (b = -1.35, 95% confidence interval [CI]: -1.68, -1.02), with complete TL alone (b = -0.67, 95% CI: -0.88, -0.45), or with DM alone (b = -0.40, 95% CI: -0.59, -0.22), had lower cognitive scores. The impact of having both conditions was significantly greater than that of having DM alone (p < .001) or complete TL alone (p = 0.001). Sex-stratified analyses showed the effects were similar in males and females, except having DM alone was not significant in males. CONCLUSION The co-occurrence of DM and complete TL poses an additive risk for cognition. Healthcare and family-care providers should pay attention to the cognitive health of patients with both DM and complete TL. Continued efforts are needed to improve older adults' access to dental care, especially for individuals with DM.
Collapse
Affiliation(s)
- Huabin Luo
- East Carolina University, Brody School of Medicine, Greenville, USA
| | - Chenxin Tan
- New York University, Rory Meyers College of Nursing New York, USA
| | | | | | - Angela Kamer
- New York University College of Dentistry, New York, USA
| | - Frank Sloan
- Duke University School of Medicine, Durham, USA
| | - Mark Schwartz
- New York University Grossman School of Medicine, New York, USA
| | - Xiang Qi
- New York University, Rory Meyers College of Nursing New York, USA
| | - Bei Wu
- New York University, Rory Meyers College of Nursing New York, USA
| |
Collapse
|
30
|
Frison E, Dufouil C, Helmer C, Berr C, Auriacombe S, Chêne G. Diabetes-Associated Dementia Risk and Competing Risk of Death in the Three-City Study. J Alzheimers Dis 2020; 71:1339-1350. [PMID: 31524165 DOI: 10.3233/jad-190427] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Diabetes is associated with a higher dementia and mortality risk. However, few studies have accounted for death when estimating the association between diabetes and dementia. We estimated absolute and relative risks of all-cause dementia according to diabetes exposure status in older adults while accounting for competing risk of death using illness-death models. Effect modification by specific characteristics (age, gender, education, cardiovascular risk factors, body mass index, cardiovascular history, depressive symptomatology, impaired renal function, and APOEɛ4 genotype) was also investigated. We analyzed the Three-City study data, a French population-based cohort of adults aged 65 years and above who were followed up for 12 years from 1999-2001. Among 8,328 participants selected in the analytical sample (median age, 73.3 years; 60.3% women), 809 (9.3%) presented with diabetes at baseline. Over a median follow-up period of 8.3 years, 836 participants developed incident dementia. Baseline diabetes was associated with a higher risk of dementia: hazard ratio, 1.79 [95% confidence interval, 1.46-2.19]. No effect modification was shown. Diabetes was associated with a higher 12-year absolute risk of dementia and a lower dementia-free life expectancy (e.g., 14.5% [11.2-18.1] versus 8.7% [7.6-10.2], and 13.4 [12.7-14.1] years versus 16.5 [16.0-17.1] years, respectively, for a 70-year-old woman with the highest level of education). These findings support the potential impact of preventing diabetes on reducing dementia risk in older adults, with a 2-3-year higher dementia-free life expectancy for individuals without diabetes, and inform the design of future interventional trials.
Collapse
Affiliation(s)
- Eric Frison
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Team VINTAGE, UMR 1219 and Inserm, CIC1401-EC, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France
| | - Carole Dufouil
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Team VINTAGE, UMR 1219 and Inserm, CIC1401-EC, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France
| | - Catherine Helmer
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, CHU Bordeaux, Bordeaux, France; Inserm, CIC1401-EC, Bordeaux, France
| | - Claudine Berr
- Université de Montpellier, Inserm, U1061, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France
| | - Sophie Auriacombe
- CHU Bordeaux Centre Mémoire Ressource et Recherche/ Institut des Maladies Neurodégénératives clinique (IMNc) Hopital Pellegrin, Bordeaux, France
| | - Geneviève Chêne
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Team VINTAGE, UMR 1219 and Inserm, CIC1401-EC, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France
| |
Collapse
|
31
|
Andrews RM, Shpitser I, Lopez O, Longstreth WT, Chaves PHM, Kuller L, Carlson MC. Examining the causal mediating role of brain pathology on the relationship between diabetes and cognitive impairment: the Cardiovascular Health Study. JOURNAL OF THE ROYAL STATISTICAL SOCIETY. SERIES A, (STATISTICS IN SOCIETY) 2020; 183:1705-1726. [PMID: 34321718 PMCID: PMC8314961 DOI: 10.1111/rssa.12570] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
The paper examines whether diabetes mellitus leads to incident mild cognitive impairment and dementia through brain hypoperfusion and white matter disease. We performed inverse odds ratio weighted causal mediation analyses to decompose the effect of diabetes on cognitive impairment into direct and indirect effects, and we found that approximately a third of the total effect of diabetes is mediated through vascular-related brain pathology. Our findings lend support for a common aetiological hypothesis regarding incident cognitive impairment, which is that diabetes increases the risk of clinical cognitive impairment in part by impacting the vasculature of the brain.
Collapse
Affiliation(s)
- Ryan M Andrews
- Johns Hopkins University, Baltimore, USA, and Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany
| | | | - Oscar Lopez
- University of Pittsburgh School of Medicine, USA
| | | | | | | | - Michelle C Carlson
- Johns Hopkins University, Baltimore, and Johns Hopkins Center on Aging and Health, Baltimore, USA
| |
Collapse
|
32
|
Yang G, Deng N, Liu Y, Gu Y, Yao X. Evaluation of Glymphatic System Using Diffusion MR Technique in T2DM Cases. Front Hum Neurosci 2020; 14:300. [PMID: 32922272 PMCID: PMC7456821 DOI: 10.3389/fnhum.2020.00300] [Citation(s) in RCA: 84] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 07/06/2020] [Indexed: 01/10/2023] Open
Abstract
Objective: We aimed to evaluate the activity of the human glymphatic system in type 2 diabetes mellitus (T2DM) using diffusion tensor image analysis along with the perivascular space (DTI-ALPS). Methods: Diffusion tensor images were acquired to calculate the diffusivities in the direction of the x-axis (right-to-left; Dx), y-axis (anterior-to-posterior; Dy), and z-axis (inferior-to-superior; Dz) of the plane of the lateral ventricle body in 20 patients with type 2 diabetes and 10 people in a control group. We evaluated the diffusivity along with the perivascular spaces, as well as the projection fibers and association fibers, separately. The analysis along the perivascular space (ALPS-index) was defined as the mean (Dxpro, Dypro)/mean (Dypro, Dzasc), where the Dxpro and Dxasc were the Dx values in the projection and association fiber areas, respectively. Results: There were significant differences in diffusivity along the projection fibers and the association fibers among the groups. The significant differences among the groups along the perivascular spaces, shown as the ALPS-index and medical history of T2DM, indicating lower water diffusivity along the perivascular space concerning type 2 diabetes severity, was also observed. Conclusion: Lower diffusivity along the perivascular space on DTI-APLS can reflect impairment of the glymphatic system in T2DM. This study showed that the activity of the glymphatic system could be evaluated by diffusion tensor image analysis.
Collapse
Affiliation(s)
- Guangwei Yang
- Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, China
| | - Nan Deng
- Luzhou People's Hospital, Luzhou, China
| | - Yi Liu
- Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, China
| | - Yingjiang Gu
- Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, China
| | - Xiang Yao
- Department of Radiology, Xiang'an Hospital of Xiamen University, Xiamen, China
| |
Collapse
|
33
|
Wang S, Lv W, Zhang H, Liu Y, Li L, Jefferson JR, Guo Y, Li M, Gao W, Fang X, Paul IA, Rajkowska G, Shaffery JP, Mosley TH, Hu X, Liu R, Wang Y, Yu H, Roman RJ, Fan F. Aging exacerbates impairments of cerebral blood flow autoregulation and cognition in diabetic rats. GeroScience 2020; 42:1387-1410. [PMID: 32696219 DOI: 10.1007/s11357-020-00233-w] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 07/08/2020] [Indexed: 02/06/2023] Open
Abstract
Diabetes mellitus (DM) is a leading risk factor for aging-related dementia; however, the underlying mechanisms are not well understood. The present study, utilizing a non-obese T2DN diabetic model, demonstrates that the myogenic response of the middle cerebral artery (MCA) and parenchymal arteriole (PA) and autoregulation of cerebral blood flow (CBF) in the surface and deep cortex were impaired at both young and old ages. The impaired CBF autoregulation was more severe in old than young DM rats, and in the deep than the surface cortex. The myogenic tone of the MCA was enhanced at perfusion pressure in the range of 40-100 mmHg in young DM rats but was reduced at 140-180 mmHg in old DM rats. No change of the myogenic tone of the PA was observed in young DM rats, whereas it was significantly reduced at 30-60 mmHg in old DM rats. Old DM rats had enhanced blood-brain barrier (BBB) leakage and neurodegeneration, reduced vascular density, tight junction, and pericyte coverage on cerebral capillaries in the CA3 region in the hippocampus. Additionally, DM rats displayed impaired functional hyperemia and spatial learning and short- and long-term memory at both young and old ages. Old DM rats had impaired non-spatial short-term memory. These results revealed that impaired CBF autoregulation and enhanced BBB leakage plays an essential role in the pathogenesis of age- and diabetes-related dementia. These findings will lay the foundations for the discovery of anti-diabetic therapies targeting restoring CBF autoregulation to prevent the onset and progression of dementia in elderly DM.
Collapse
Affiliation(s)
- Shaoxun Wang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Wenshan Lv
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.,Department of Endocrinology and Metabolic, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China
| | - Huawei Zhang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Yedan Liu
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Longyang Li
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Joshua R Jefferson
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Ya Guo
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Man Li
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Wenjun Gao
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Xing Fang
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Ian A Paul
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - Grazyna Rajkowska
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - James P Shaffery
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - Thomas H Mosley
- Department of Neurology, University of Mississippi Medical Center, Jackson, MS, 39216, USA.,Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - Xinlin Hu
- Department of Endocrinology and Metabolic, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China
| | - Ruen Liu
- Department of Neurosurgery, Peking University People's Hospital, Beijing, 100044, China
| | - Yangang Wang
- Department of Endocrinology and Metabolic, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China
| | - Hongwei Yu
- Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA
| | - Richard J Roman
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - Fan Fan
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
| |
Collapse
|
34
|
Bayes-Marin I, Sanchez-Niubo A, Egea-Cortés L, Nguyen H, Prina M, Fernández D, Haro JM, Olaya B. Multimorbidity patterns in low-middle and high income regions: a multiregion latent class analysis using ATHLOS harmonised cohorts. BMJ Open 2020; 10:e034441. [PMID: 32690500 PMCID: PMC7371222 DOI: 10.1136/bmjopen-2019-034441] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 05/17/2020] [Accepted: 05/27/2020] [Indexed: 12/26/2022] Open
Abstract
OBJECTIVES Our aim was to determine clusters of non-communicable diseases (NCDs) in a very large, population-based sample of middle-aged and older adults from low- and middle-income (LMICs) and high-income (HICs) regions. Additionally, we explored the associations with several covariates. DESIGN The total sample was 72 140 people aged 50+ years from three population-based studies (English Longitudinal Study of Ageing, Survey of Health, Ageing and Retirement in Europe Study and Study on Global Ageing and Adult Health) included in the Ageing Trajectories of Health: Longitudinal Opportunities and Synergies (ATHLOS) project and representing eight regions with LMICs and HICs. Variables were previously harmonised using an ex-post strategy. Eight NCDs were used in latent class analysis. Multinomial models were made to calculate associations with covariates. All the analyses were stratified by age (50-64 and 65+ years old). RESULTS Three clusters were identified: 'cardio-metabolic' (8.93% in participants aged 50-64 years and 27.22% in those aged 65+ years), 'respiratory-mental-articular' (3.91% and 5.27%) and 'healthy' (87.16% and 67.51%). In the younger group, Russia presented the highest prevalence of the 'cardio-metabolic' group (18.8%) and England the 'respiratory-mental-articular' (5.1%). In the older group, Russia had the highest proportion of both classes (48.3% and 9%). Both the younger and older African participants presented the highest proportion of the 'healthy' class. Older age, being woman, widowed and with low levels of education and income were related to an increased risk of multimorbidity. Physical activity was a protective factor in both age groups and smoking a risk factor for the 'respiratory-mental-articular'. CONCLUSION Multimorbidity is common worldwide, especially in HICs and Russia. Health policies in each country addressing coordination and support are needed to face the complexity of a pattern of growing multimorbidity.
Collapse
Affiliation(s)
- Ivet Bayes-Marin
- Research, Innovation and Teaching Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
- Department of Medicine, Universitat de Barcelona, Barcelona, Spain
| | - Albert Sanchez-Niubo
- Research, Innovation and Teaching Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
| | - Laia Egea-Cortés
- Center of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain
| | - Hai Nguyen
- Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Matthew Prina
- Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Daniel Fernández
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
- Serra Húnter fellow. Department of Statistics and Operations Research, Polytechnic University of Catalonia, Barcelona, Spain
| | - Josep Maria Haro
- Research, Innovation and Teaching Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
- Department of Medicine, Universitat de Barcelona, Barcelona, Spain
| | - Beatriz Olaya
- Research, Innovation and Teaching Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
| |
Collapse
|
35
|
Ortiz K, Garcia MA, Briceño E, Diminich ED, Arévalo SP, Vega IE, Tarraf W. Glycosylated hemoglobin level, race/ethnicity, and cognition in midlife and early old age. RESEARCH IN HUMAN DEVELOPMENT 2020; 17:20-40. [PMID: 34093090 PMCID: PMC8174791 DOI: 10.1080/15427609.2020.1743810] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Empirical evidence linking racial/ethnic differences in glycosylated hemoglobin levels (HbA1c) to cognitive function in midlife and early old age is limited. We use biomarker data from the Health and Retirement Study (HRS, 2006-2014), on adults 50-64 years at baseline (57-73 years by 2014), and fit multinomial logistic regression models to assess the association between baseline HbA1c, cognitive function (using Langa-Weir classifications) and mortality across 8-years. Additionally, we test for modification effects by race/ethnicity. In age- and sex-adjusted models high HbA1c level was associated with lower baseline cognition and higher relative risk ratios (RRR; vs. normal cognition) for cognitive impairment no dementia (CIND; RRR= 2.3; 95%CI=[1.38;3.84]; p<0.01), and dementia (RRR= 4.00; 95%CI=[1.76;9.10]; p<0.01). Adjusting for sociodemographic, behavioral risk factors, and other health conditions explained the higher RRR for CIND and attenuated the RRR for dementia by approximately 30%. HbA1c levels were not linked to the slope of cognitive decline, and we found no evidence of modification effects for HbA1c by race/ethnicity. Targeting interventions for glycemic control in the critical midlife period can protect baseline cognition and buffer against downstream development of cognitive impairment. This can yield important public health benefits and reductions in burdens associated with cognitive impairment, particularly among race/ethnic minorities who are at higher risk for metabolic diseases.
Collapse
Affiliation(s)
- Kasim Ortiz
- University of New Mexico, Department of Sociology & Criminology, Institute for the Study of “Race” & Social Justice, Center for Participatory Research
| | - Marc A. Garcia
- University of Nebraska, Lincoln, Department of Sociology & Institute of Ethnic Studies
| | - Emily Briceño
- University of Michigan, School of Medicine, Department of Physical Medicine & Rehabilitation
| | - Erica D. Diminich
- Stony Brook University, Renaissance School of Medicine, Program in Public Health, Department of Family, Population and Preventive Medicine
| | - Sandra P. Arévalo
- California State University, Long Beach, Department of Human Development
| | - Irving E. Vega
- Michigan State University, College of Human Medicine, Department of Translational Neuroscience
| | - Wassim Tarraf
- Wayne State University, Institute of Gerontology & Department of Healthcare Sciences
| |
Collapse
|
36
|
Abstract
Dementia and type 2 diabetes are a serious public health problem worldwide, with increasing incidence with age. Diabetes is a risk factor for the development of dementia. Having cognitive dysfunction impairs a person's ability to perform self-care tasks. Also, community dwelling adults can have varying levels of functional impairment and can also have other geriatric syndromes. This article presents a multidisciplinary approach and treatment and goals tailored individually to patients with different levels of cognitive and activities of daily living impairments. Three case studies show the management of diabetes in older adults with different levels of care needs.
Collapse
Affiliation(s)
- Sathya Reddy
- Cleveland Clinic, 5700 Cooper Foster Park Road, Lorain, OH 44053, USA.
| | - Ardeshir Hashmi
- Cleveland Clinic, Center for Geriatric Medicine, 9500 Euclid Avenue, X10, Cleveland, OH 44195, USA
| |
Collapse
|
37
|
Kaur J, Davoodi-Bojd E, Fahmy LM, Zhang L, Ding G, Hu J, Zhang Z, Chopp M, Jiang Q. Magnetic Resonance Imaging and Modeling of the Glymphatic System. Diagnostics (Basel) 2020; 10:diagnostics10060344. [PMID: 32471025 PMCID: PMC7344900 DOI: 10.3390/diagnostics10060344] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 05/22/2020] [Accepted: 05/25/2020] [Indexed: 12/20/2022] Open
Abstract
The glymphatic system is a newly discovered waste drainage pathway in the brain; it plays an important role in many neurological diseases. Ongoing research utilizing various cerebrospinal fluid tracer infusions, either directly or indirectly into the brain parenchyma, is investigating clearance pathways by using distinct imaging techniques. In the present review, we discuss the role of the glymphatic system in various neurological diseases and efflux pathways of brain waste clearance based on current evidence and controversies. We mainly focus on new magnetic resonance imaging (MRI) modeling techniques, along with traditional computational modeling, for a better understanding of the glymphatic system function. Future sophisticated modeling techniques hold the potential to generate quantitative maps for glymphatic system parameters that could contribute to the diagnosis, monitoring, and prognosis of neurological diseases. The non-invasive nature of MRI may provide a safe and effective way to translate glymphatic system measurements from bench-to-bedside.
Collapse
Affiliation(s)
- Jasleen Kaur
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
- Department of Physics, Oakland University, Rochester, MI 48309, USA
| | - Esmaeil Davoodi-Bojd
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
- Department of Radiology, Henry Ford Health System, Detroit, MI 48202, USA
| | - Lara M Fahmy
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
- Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI 48201, USA
| | - Li Zhang
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
| | - Guangliang Ding
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
| | - Jiani Hu
- Department of Radiology, Wayne State University, Detroit, MI 48201, USA;
| | - Zhenggang Zhang
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
| | - Michael Chopp
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
- Department of Physics, Oakland University, Rochester, MI 48309, USA
| | - Quan Jiang
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA; (J.K.); (E.D.-B.); (L.M.F.); (L.Z.); (G.D.); (Z.Z.); (M.C.)
- Department of Physics, Oakland University, Rochester, MI 48309, USA
- Correspondence: ; Tel.: +1-313-916-8735; Fax: +1-313-916-1324
| |
Collapse
|
38
|
Mauricio D, Alonso N, Gratacòs M. Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends Endocrinol Metab 2020; 31:287-295. [PMID: 32033865 DOI: 10.1016/j.tem.2020.01.007] [Citation(s) in RCA: 89] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 11/22/2019] [Accepted: 01/09/2020] [Indexed: 12/11/2022]
Abstract
Chronic-diabetes-related complications simultaneously compromise both the micro- and macrovascular trees, with target organs considered as the paradigm of large vessel injury also entailing microangiopathic changes. However, complications independent or partially independent from vascular damage are often overlooked. This includes neuronal dysfunction (e.g., retinal neurodegeneration), interstitial injury (e.g., tubulointerstitial disease), metabolic damage (e.g., in the heart and liver), and nonclassical conditions such as cognitive decline, impaired pulmonary function, or increased risk of cancer. In this scenario, researchers, endocrinologists and primary care physicians should have a holistic view of the disease and pay further attention to all organs and all potential clinical repercussions, which would certainly contribute to a more rational and integrated patient health care.
Collapse
Affiliation(s)
- Dídac Mauricio
- DAP-Cat group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
| | - Núria Alonso
- CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain; Department of Endocrinology and Nutrition, Health Sciences Research Institute & University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Mònica Gratacòs
- DAP-Cat group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
| |
Collapse
|
39
|
Liu W, Zhang P, Tan J, Lin Y. Differentiation of Urine-Derived Induced Pluripotent Stem Cells to Neurons, Astrocytes, and Microvascular Endothelial Cells from a Diabetic Patient. Cell Reprogram 2020; 22:147-155. [PMID: 32207986 DOI: 10.1089/cell.2019.0088] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Complications of central nervous system in type 2 diabetes mellitus (T2DM) often lead to cognitive impairment and seriously affect the quality of life. However, there is no individualized disease model. Urine-derived stem cells can be an ideal source for generating human induced pluripotent stem cells (hiPSCs) and progenitors, as they are easily accessible, noninvasive, and universally available. In our research, we differentiated urine-derived hiPSCs into neuron (N), astrocyte (A), and microvascular endothelial cells (E) from a T2DM patient. Next step, we intend to coculture these three cells together in a 3D system to create a new disease model in vitro, which may simulate the cerebral microenvironment of DM, for future study of its pathogenesis and precision medical treatment.
Collapse
Affiliation(s)
- Wan Liu
- Department of Neurology, the Second Hospital of Dalian Medical University, Dalian City, China
| | - Ping Zhang
- Department of Endocrinology, the Second Hospital of Dalian Medical University, Dalian City, China
| | - Jing Tan
- Department of Neurology, the Second Hospital of Dalian Medical University, Dalian City, China
| | - Yongzhong Lin
- Department of Neurology, the Second Hospital of Dalian Medical University, Dalian City, China
| |
Collapse
|
40
|
Demographic Factors and Cognitive Function Assessments Associated with Mild Cognitive Impairment Progression for the Elderly. BIOMED RESEARCH INTERNATIONAL 2020; 2020:3054373. [PMID: 32090075 PMCID: PMC7031731 DOI: 10.1155/2020/3054373] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 09/24/2019] [Accepted: 10/16/2019] [Indexed: 01/09/2023]
Abstract
Objectives In this study, we aimed to conduct a 6-year follow-up and acquire a large sample dataset to analyze the most important demographic factors and cognitive function scale variables associated with mild cognitive impairment (MCI) progression for an elderly cohort (age ≥ 60 years old). Patients and Methods. We analyzed the subjects who had participated in a survey in 2011 and were successfully contacted in the later survey in 2017. For each subject, the basic demographic information was recorded, including sex, age, education level, marital status, working status, income level, and physical mental illness history. Cognitive assessments were performed using the following scales if possible: (1) the mini-mental state examination (MMSE) scale, (2) Montreal cognitive assessment (MoCA), (3) the clinical dementia rating (CDR) scale, and (4) Hamilton Depression Scale (HAMD-17). Results The progression outcomes were different between sexes, among age brackets, education degrees, occupations types, and income levels; different progression groups had distinct children numbers (p < 0.001), heights (p < 0.001), heights (p < 0.001), heights (p < 0.001), heights ( Conclusions In conclusion, the MCI progression outcomes were associated with sex, age, education degrees, occupations types, income level, children number, height, and weight. MoCA and MMSE scales are supporting tools to predict the progression outcomes, especially combined with the demographic data.
Collapse
|
41
|
The activation of immunoglobulin G Fc receptors (FcγRs) with immunoreceptor tyrosine-based activation motifs (ITAMs) promotes cognitive impairment in aged rats with diabetes. Exp Gerontol 2019; 125:110660. [PMID: 31319129 DOI: 10.1016/j.exger.2019.110660] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 06/10/2019] [Accepted: 07/14/2019] [Indexed: 02/05/2023]
Abstract
AIMS Although immunoglobulin G Fc receptors with immunoreceptor tyrosine-based activation motifs (ITAM-FcγRs) have been implicated in the mediation of inflammatory responses, the importance of these receptors in the pathogenesis of cognitive impairment in geriatric diabetes remains unclear. The present study investigated the potential role of ITAM-FcγRs in cognitive impairment in geriatric diabetes. METHODS Diabetes was induced by streptozotocin (STZ) in aged Wistar rats, and cognitive function and cerebral injury were assessed 8 weeks later using the Morris water maze (MWM), real-time PCR and Western blot. In vitro, the inhibition of ITAM-FcγRs was investigated using rat chromaffin cells cultured with high glucose. RESULTS Aged rats with diabetes exhibited marked and persistent learning and memory impairments. Enhanced cerebral inflammation in the diabetic aged rats was associated with the overactivation of the nuclear factor κB (NF-κB) signaling pathway and the upregulation of inflammatory cytokines (interleukin-6 (IL-6) and tumor nuclear factor-α (TNF-α)) in the hippocampus. Compared to no treatment, the knockdown of FcγRIV (the main isoform of ITAM-FcγRs) markedly attenuated cognitive impairment as well as histologic and ultrastructural pathologic changes in the diabetic rats. The increased expression of inflammatory cytokines and the overactivation of the NF-κB signaling pathway were also significantly alleviated. In vitro, high glucose concentrations significantly activated the NF-κB signaling pathway and increased the expression of inflammatory cytokines. The inhibition of FcγR expression by a small interfering RNA and/or a FcγRI- and FcγRIII-neutralizing antibody significantly ameliorated the effects mediated by high glucose. CONCLUSION The enhanced activation of the NF-κB signalling pathway may be the mechanism by which ITAM-FcγRs promote cerebral inflammation and cognitive impairment in diabetes. ITAM-FcγRs may be viewed as a potential target for preventative intervention for cognitive impairment in older adults with diabetes.
Collapse
|
42
|
Nilsson M, Jensen N, Gejl M, Bergmann ML, Storgaard H, Zander M, Miskowiak K, Rungby J. Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial. Diabetologia 2019; 62:1948-1958. [PMID: 31367958 DOI: 10.1007/s00125-019-4964-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Accepted: 06/21/2019] [Indexed: 12/27/2022]
Abstract
AIMS/HYPOTHESIS Previous studies have demonstrated a relationship between cognitive impairment and hypoglycaemia (<3 mmol/l). This study hypothesised that non-severe insulin-induced hypoglycaemia reduces cognitive function in individuals with type 2 diabetes. METHODS In this randomised crossover study, 25 participants with type 2 diabetes attended two experimental visits with hyperinsulinaemic glucose clamping: one hypoglycaemic clamp (plasma glucose 3.0 ± 0.2 mmol/l) and one euglycaemic clamp (plasma glucose 6.0 ± 0.2 mmol/l). Participants were eligible if their diabetes was treated with diet or glucose-lowering medications (except sulfonylureas or insulin), age was 35-70 years, BMI was 23-35 kg/m2 and HbA1c was below 75 mmol/mol (9%). Cognitive function was assessed with a neurocognitive test battery measuring verbal memory, executive function, sustained attention and psychomotor speed. From the examined cognitive domains, a global cognition score was constructed estimating global cognition. A measurement for psychomotor speed was selected as the primary outcome. Participants and people assessing the outcomes were blinded to group assignment. RESULTS Cognitive performance was impaired during hypoglycaemia with a mean score in the primary outcome test, Symbol Digit Modalities Test measuring psychomotor speed, of 48.7 ± 9.8 (hypoglycaemia) vs 56.6 ± 12.0 (euglycaemia); i.e. a change of -7.9 points (95% CI -10.9, -4.9; p < 0.0001). In addition, hypoglycaemia reduced global cognitive score by -0.7 (95% CI -0.9, -0.6; p < 0.0001). A stable glucose plateau was achieved during both experimental visits. For the hypoglycaemic clamp, mean plasma glucose concentration (± SD) during neurocognitive testing was 3.1 (± 0.3) mmol/l. Age, sex, fasting C-peptide, counter-regulatory hormones and the severity of hypoglycaemic symptoms did not influence cognitive function. CONCLUSIONS/INTERPRETATION Acute non-severe hypoglycaemia (mean plasma glucose 3.1 mmol/l) has a substantial negative impact on cognitive function in individuals with type 2 diabetes. TRIAL REGISTRATION ClinicalTrials.gov NCT03014011. FUNDING The study was supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp (MSD-MA-NORD-007-01). The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. Funding was also received from Skibsreder Per Henriksen, R. og hustrus Foundation, The Danish Alzheimer Foundation and Savværksejer Jeppe Juhl og hustrus Foundation.
Collapse
Affiliation(s)
- Malin Nilsson
- Department of Endocrinology, Bispebjerg University Hospital, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark.
| | - Nicole Jensen
- Department of Endocrinology, Bispebjerg University Hospital, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark
| | - Michael Gejl
- Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark
| | - Marianne L Bergmann
- Department of Biochemistry and Immunology, University Hospital of Southern Denmark, Vejle, Denmark
| | - Heidi Storgaard
- Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, Hellerup, Denmark
| | - Mette Zander
- Department of Endocrinology, Bispebjerg University Hospital, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark
| | - Kamilla Miskowiak
- Department of Psychology and Mental Health Services, University of Copenhagen, Copenhagen, Denmark
- Psychiatric Centre Copenhagen, Rigshospitalet, Denmark
| | - Jørgen Rungby
- Department of Endocrinology, Bispebjerg University Hospital, Bispebjerg Bakke 23, 2400, Copenhagen, NV, Denmark
- Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark
- Copenhagen Center for Translational Research, Bispebjerg University Hospital, Copenhagen, Denmark
| |
Collapse
|
43
|
Litchman ML, Wawrzynski SE, Allen NA, Tracy EL, Kelly CS, Helgeson VS, Berg CA. Yours, Mine, and Ours: A Qualitative Analysis of the Impact of Type 1 Diabetes Management in Older Adult Married Couples. Diabetes Spectr 2019; 32:239-248. [PMID: 31462880 PMCID: PMC6695253 DOI: 10.2337/ds18-0057] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE The purpose of this study was to understand perceptions of diabetes management responsibilities and the impact of diabetes on day-to-day activities in older adulthood for individuals with type 1 diabetes and their spouses. DESIGN AND METHODS This qualitative content analysis used a constant-compare approach to analyze individual interviews conducted with older adults and their spouses. People with type 1 diabetes (PWD) and their spouses were interviewed regarding how they coped or dealt with diabetes, what activities they carried out or avoided because of diabetes, and how they appraised diabetes as an individual or shared problem. RESULTS Participants (n = 52) included 26 older adults with diabetes (mean age 69 years, SD 2.56 years; 38.5% female) and their spouses (mean age 68 years, SD 5.11 years; 61.5% female). Half of the PWD (50%) and the majority of spouses (76.9%) appraised diabetes as a shared issue. Five themes emerged from the interview data: 1) Perceptions pf PWD of spouse involvement in diabetes care, 2) PWD underestimated the impact of diabetes on their spouse's daily lives, 3) gendered nature of spouses supporting diabetes management, 4) evolution of diabetes and the relationship across developmental time, and 5) differences in diabetes management among couples. CONCLUSION Older adults with type 1 diabetes and their spouses have different perspectives regarding diabetes support and responsibility and may not always realize what support is being provided or needed to optimize effective diabetes management. Advancing age with or without diabetes complications may necessitate that spouses provide diabetes support. Diabetes management training for spouses would likely be helpful.
Collapse
Affiliation(s)
- Michelle L. Litchman
- University of Utah College of Nursing, Salt Lake City, UT
- Utah Diabetes and Endocrinology Center, Salt Lake City, UT
| | | | - Nancy A. Allen
- University of Utah College of Nursing, Salt Lake City, UT
| | - Eunjin L. Tracy
- Department of Psychology, University of Utah, Salt Lake City, UT
| | - Caitlin S. Kelly
- Department of Psychology, University of Utah, Salt Lake City, UT
| | - Vicki S. Helgeson
- Department of Psychology, Carnegie Mellon University, Pittsburgh, PA
| | - Cynthia A. Berg
- Department of Psychology, University of Utah, Salt Lake City, UT
| |
Collapse
|
44
|
|
45
|
Cholerton B, Omidpanah A, Verney SP, Nelson LA, Baker LD, Suchy-Dicey A, Longstreth WT, Howard BV, Henderson JA, Montine TJ, Buchwald D. Type 2 diabetes and later cognitive function in older American Indians: The Strong Heart Study. Int J Geriatr Psychiatry 2019; 34:1050-1057. [PMID: 30924200 PMCID: PMC6579638 DOI: 10.1002/gps.5108] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 11/29/2018] [Indexed: 01/17/2023]
Abstract
OBJECTIVES Insulin resistance is a substantial health issue for American Indians, with type 2 diabetes overrepresented in this population as compared with non-Hispanic whites. Insulin resistance and its related conditions in turn increase risk for dementia and cognitive impairment. The aim of the current study was to determine whether type 2 diabetes and insulin resistance at midlife was associated with later-life cognitive testing in a large sample of older American Indians, aged 65 and older. METHODS American Indian participants who underwent both fasting blood draw as part of the Strong Heart Study and had subsequent cognitive testing as part of the later adjunct Cerebrovascular Disease and its Consequences in American Indians study were included (n = 790). Regression models examined type 2 diabetes and impaired fasting glucose and subsequent cognitive test performance as part of a longitudinal study design. The relationship between a continuous measure of insulin resistance and later cognitive test performance was assessed using generalized estimating equations. RESULTS Controlling for demographic and clinical factors, verbal fluency and processing speed/working memory were significantly negatively associated with having type 2 diabetes and with insulin resistance, but not with impaired fasting glucose. CONCLUSION In this sample of American Indians, type 2 diabetes at midlife was associated with subsequent lower performance on measures of executive function. These results may have important implications for future implementation of diagnostic and intervention services in this population.
Collapse
Affiliation(s)
- Brenna Cholerton
- Department of Pathology, Stanford University, Palo Alto, California, USA
| | - Adam Omidpanah
- Department of Community Health, Washington State University, Seattle, Washington, USA
| | - Steven P. Verney
- Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA
| | - Lonnie A. Nelson
- Department of Community Health, Washington State University, Seattle, Washington, USA
| | - Laura D. Baker
- Department of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Astrid Suchy-Dicey
- Department of Community Health, Washington State University, Seattle, Washington, USA
| | - William T. Longstreth
- Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA,Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA
| | | | | | - Thomas J. Montine
- Department of Pathology, Stanford University, Palo Alto, California, USA
| | - Dedra Buchwald
- Department of Community Health, Washington State University, Seattle, Washington, USA
| |
Collapse
|
46
|
Silva AR, Grosso C, Delerue-Matos C, Rocha JM. Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity. Eur J Med Chem 2019; 174:87-115. [PMID: 31029947 DOI: 10.1016/j.ejmech.2019.04.028] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 04/10/2019] [Accepted: 04/11/2019] [Indexed: 02/06/2023]
Abstract
Given their therapeutic activity, natural products have been used in traditional medicines throughout the centuries. The growing interest of the scientific community in phytopharmaceuticals, and more recently in marine products, has resulted in a significant number of research efforts towards understanding their effect in the treatment of neurodegenerative diseases, such as Alzheimer's (AD), Parkinson (PD) and Huntington (HD). Several studies have shown that many of the primary and secondary metabolites of plants, marine organisms and others, have high affinities for various brain receptors and may play a crucial role in the treatment of diseases affecting the central nervous system (CNS) in mammalians. Actually, such compounds may act on the brain receptors either by agonism, antagonism, allosteric modulation or other type of activity aimed at enhancing a certain effect. The current manuscript comprehensively reviews the state of the art on the interactions between natural compounds and brain receptors. This information is of foremost importance when it is intended to investigate and develop cutting-edge drugs, more effective and with alternative mechanisms of action to the conventional drugs presently used for the treatment of neurodegenerative diseases. Thus, we reviewed the effect of 173 natural products on neurotransmitter receptors, diabetes related receptors, neurotrophic factor related receptors, immune system related receptors, oxidative stress related receptors, transcription factors regulating gene expression related receptors and blood-brain barrier receptors.
Collapse
Affiliation(s)
- Ana R Silva
- Centre of Molecular and Environmental Biology (CBMA), Department of Biology (DB), University of Minho (UM), Campus Gualtar, P-4710-057, Braga, Portugal
| | - Clara Grosso
- REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, P-4249-015, Porto, Portugal.
| | - Cristina Delerue-Matos
- REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, P-4249-015, Porto, Portugal
| | - João M Rocha
- Centre of Molecular and Environmental Biology (CBMA), Department of Biology (DB), University of Minho (UM), Campus Gualtar, P-4710-057, Braga, Portugal; REQUIMTE/LAQV, Grupo de investigação de Química Orgânica Aplicada (QUINOA), Laboratório de polifenóis alimentares, Departamento de Química e Bioquímica (DQB), Faculdade de Ciências da Universidade do Porto (FCUP), Rua do Campo Alegre, s/n, P-4169-007, Porto, Portugal
| |
Collapse
|
47
|
Mucellini AB, Laureano DP, Silveira PP, Sanvitto GL. Maternal and post-natal obesity alters long-term memory and hippocampal molecular signaling of male rat. Brain Res 2019; 1708:138-145. [DOI: 10.1016/j.brainres.2018.12.021] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 12/14/2018] [Accepted: 12/15/2018] [Indexed: 12/15/2022]
|
48
|
Davoodi-Bojd E, Ding G, Zhang L, Li Q, Li L, Chopp M, Zhang Z, Jiang Q. Modeling glymphatic system of the brain using MRI. Neuroimage 2019; 188:616-627. [PMID: 30578928 PMCID: PMC6401298 DOI: 10.1016/j.neuroimage.2018.12.039] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2018] [Revised: 12/14/2018] [Accepted: 12/17/2018] [Indexed: 12/20/2022] Open
Abstract
The glymphatic system is functional waste clearance path from the brain parenchyma through dynamic exchange of cerebrospinal fluid (CSF) with interstitial fluid (ISF). Impairment of glymphatic waste clearance is involved in the development of neurodegenerative conditions. Despite many recent studies investigating the glymphatic system, few studies have tried to use a mathematical model to describe this system, quantitatively. In this study, we aim to model the glymphatic system from the kinetics of Gd-DTPA tracer measured using MRI in order to: 1) map the glymphatic system path, 2) derive kinetic parameters of the glymphatic system, and 3) provide quantitative maps of the structure and function of this system. In the proposed model, the brain is clustered to similar regions with respect to the profile of contrast agent (CA) density measured by MRI. Then, each region is described as a two-compartment kinetic model 'derived from' or 'clears to' its neighbors with local input function. We thus fit our model to the local cerebral regions rather than to the averaged time signal curve (TSC) of the whole brain. The estimated parameters showed distinctive differences between diabetes mellitus (DM) and control rats. The results suggest that in a typical DM brain the CSF bulk speed in the para-vasculature network is low. In addition, the resulting maps indicate that there may be increased binding and decreased absorbing of large molecules in a diabetic compared with a non-diabetic brain. The important contribution of this work was to fit the model to the local regions rather than to the averaged time signal curve (TSC) of the whole brain. This enabled us to derive quantitative maps of the glymphatic system from MRI.
Collapse
Affiliation(s)
- Esmaeil Davoodi-Bojd
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA; Department of Radiology, Henry Ford Health System, Detroit, MI, USA
| | - Guangliang Ding
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA
| | - Li Zhang
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA
| | - Qingjiang Li
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA
| | - Lian Li
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA
| | - Michael Chopp
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA; Department of Physics, Oakland University, Rochester, MI, USA
| | - ZhengGang Zhang
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA
| | - Quan Jiang
- Department of Neurology, Henry Ford Health System, Detroit, MI, USA; Department of Physics, Oakland University, Rochester, MI, USA.
| |
Collapse
|
49
|
Ebadi SA, Darvish P, Fard AJ, Lima BS, Ahangar OG. Hypoglycemia and cognitive function in diabetic patients. Diabetes Metab Syndr 2018; 12:893-896. [PMID: 29887517 DOI: 10.1016/j.dsx.2018.05.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Accepted: 05/14/2018] [Indexed: 01/02/2023]
Abstract
AIMS Hypoglycemia can be considered the most common complication of Diabetes Mellitus treatment. So far, controversial studies have been carried out to examine the impacts of hypoglycemia on the cognitive function. METHODS This study was conducted as case-control. The case group was 35 patients with Diabetes Mellitus Types I or II hospitalized in Imam Hussein Hospital, Tehran, Iran, who have experienced hypoglycemic attacks (glucose level below 70 mg/dl). The control group consisted of diabetic patients hospitalized in hospital, but they had no history of hypoglycemia. As the blood glucose level became in normal range and the patients' Mental status became stable, the brain cognitive function was examined using Mini-Mental State test. RESULTS The mean age of the subjects in the case and control groups was 56.77, 53.73 years old, respectively. The mean cognitive score in the control and hypoglycemic groups was 29.09 and 25.29, respectively. The mean MMSE cognitive score was significantly diminished in the hypoglycemic group (p < 0.001). CONCLUSIONS This study indicated that incidence of hypoglycemia in diabetic patients is associated with cognitive disorders. Further, there is a linear association between cognitive disorders and hypoglycemia, age and diabetes mellitus complication.
Collapse
Affiliation(s)
- Seyed Alireza Ebadi
- Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Parichehr Darvish
- Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Ali Jamshidi Fard
- Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Behnam Safarpour Lima
- Department of Neurology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Omid Gharoei Ahangar
- Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
50
|
Kim YK, Nam KI, Song J. The Glymphatic System in Diabetes-Induced Dementia. Front Neurol 2018; 9:867. [PMID: 30429819 PMCID: PMC6220044 DOI: 10.3389/fneur.2018.00867] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Accepted: 09/26/2018] [Indexed: 12/14/2022] Open
Abstract
The glymphatic system has emerged as an important player in central nervous system (CNS) diseases, by regulating the vasculature impairment, effectively controlling the clearance of toxic peptides, modulating activity of astrocytes, and being involved in the circulation of neurotransmitters in the brain. Recently, several studies have indicated decreased activity of the glymphatic pathway under diabetes conditions such as in insulin resistance and hyperglycemia. Furthermore, diabetes leads to the disruption of the blood-brain barrier and decrease of apolipoprotein E (APOE) expression and the secretion of norepinephrine in the brain, involving the impairment of the glymphatic pathway and ultimately resulting in cognitive decline. Considering the increased prevalence of diabetes-induced dementia worldwide, the relationship between the glymphatic pathway and diabetes-induced dementia should be investigated and the mechanisms underlying their relationship should be discussed to promote the development of an effective therapeutic approach in the near future. Here, we have reviewed recent evidence for the relationship between glymphatic pathway dysfunction and diabetes. We highlight that the enhancement of the glymphatic system function during sleep may be beneficial to the attenuation of neuropathology in diabetes-induced dementia. Moreover, we suggest that improving glymphatic system activity may be a potential therapeutic strategy for the prevention of diabetes-induced dementia.
Collapse
Affiliation(s)
- Young-Kook Kim
- Department of Biochemistry, Chonnam National University Medical School, Gwangju, South Korea.,Department of Biomedical Sciences, Center for Creative Biomedical Scientists, Chonnam National University, Gwangju, South Korea
| | - Kwang Il Nam
- Department of Anatomy, Chonnam National University Medical School, Gwangju, South Korea
| | - Juhyun Song
- Department of Biomedical Sciences, Center for Creative Biomedical Scientists, Chonnam National University, Gwangju, South Korea.,Department of Anatomy, Chonnam National University Medical School, Gwangju, South Korea
| |
Collapse
|